Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations

    Summary
    EudraCT number
    2013-002620-17
    Trial protocol
    ES   DE   GB   IT   BE  
    Global end of trial date
    24 May 2023

    Results information
    Results version number
    v2(current)
    This version publication date
    08 Jun 2024
    First version publication date
    24 Mar 2018
    Other versions
    v1
    Version creation reason

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    B7461001
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01970865
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Pfizer, Inc.
    Sponsor organisation address
    235 E 42nd Street, New York, United States, NY 10017
    Public contact
    Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
    Scientific contact
    Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    31 Oct 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    24 May 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of Phase 1 of the study was to assess safety and tolerability of PF-06463922 as a single agent at increasing dose levels in participants with advanced anaplastic lymphoma kinase (ALK) positive or advanced ROS1-positive non-small cell lung cancer (NSCLC) in order to estimate the Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose (RP2D). Primary objective of Phase 2 of the study was to evaluate overall (intra- and extra-cranial) and intra-cranial anti-tumor activity of single-agent PF-06463922 at RP2D in participants with advanced ALK-positive NSCLC and advanced ROS1-positive NSCLC.
    Protection of trial subjects
    This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of participants.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    08 Jan 2014
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 26
    Country: Number of subjects enrolled
    Canada: 7
    Country: Number of subjects enrolled
    France: 31
    Country: Number of subjects enrolled
    Germany: 1
    Country: Number of subjects enrolled
    Hong Kong: 2
    Country: Number of subjects enrolled
    Italy: 36
    Country: Number of subjects enrolled
    Japan: 42
    Country: Number of subjects enrolled
    Korea, Republic of: 9
    Country: Number of subjects enrolled
    Singapore: 29
    Country: Number of subjects enrolled
    Spain: 31
    Country: Number of subjects enrolled
    Switzerland: 7
    Country: Number of subjects enrolled
    Taiwan: 11
    Country: Number of subjects enrolled
    United States: 132
    Worldwide total number of subjects
    364
    EEA total number of subjects
    99
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    295
    From 65 to 84 years
    68
    85 years and over
    1

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    A total of 364 participants were enrolled in this study.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    10 mg QD (Phase 1)
    Arm description
    PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 10 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    25 mg QD (Phase 1)
    Arm description
    PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 25 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Investigational medicinal product name
    Midazolam
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Syrup
    Routes of administration
    Oral use
    Dosage and administration details
    Midazolam 2 mg was administered alone on Day -7 and concurrently with PF-06463922 on Cycle 1 Day 15.

    Arm title
    50 mg QD (Phase 1)
    Arm description
    PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 50 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    75 mg QD (Phase 1)
    Arm description
    PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 75 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    100 mg QD (Phase 1)
    Arm description
    PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered BID with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    150 mg QD (Phase 1)
    Arm description
    PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 150 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Investigational medicinal product name
    Midazolam
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Syrup
    Routes of administration
    Oral use
    Dosage and administration details
    Midazolam 2 mg was administered alone on Day -7 and concurrently with PF-06463922 on Cycle 1 Day 15.

    Arm title
    200 mg QD (Phase 1)
    Arm description
    PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 200 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    35 mg BID (Phase 1)
    Arm description
    PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 35 mg was administered BID with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    75 mg BID (Phase 1)
    Arm description
    PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 75 mg was administered BID with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    100 mg BID (Phase 1)
    Arm description
    PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered BID with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    EXP-1 (Phase 2)
    Arm description
    Treatment-naïve participants with advanced ALK-positive NSCLC with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    EXP-2 (Phase 2)
    Arm description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    EXP-3 (Phase 2)
    Arm description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    EXP-4 (Phase 2)
    Arm description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    EXP-5 (Phase 2)
    Arm description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    EXP-6 (Phase 2)
    Arm description
    Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    Japan Lead-In Cohort (LIC)
    Arm description
    Few Japanese participants were given PF-06463922 100 mg orally once daily (QD) in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal to evaluate safety of PF-06463922 in Japanese participants, in order to support inclusion of Japanese participants in Phase 2.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Arm title
    DDI Substudy
    Arm description
    Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1.
    Arm type
    Experimental

    Investigational medicinal product name
    PF-06463922
    Investigational medicinal product code
    Other name
    Lorlatinib
    Pharmaceutical forms
    Tablet
    Routes of administration
    Intratumoral use, Oral use
    Dosage and administration details
    PF-06463922 100 mg was administered QD with at least 240 mL of water on an empty stomach. No food or liquids other than water were consumed for 2 hours before and 2 hours following each dose.

    Number of subjects in period 1
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) Japan Lead-In Cohort (LIC) DDI Substudy
    Started
    3
    3
    3
    12
    17
    3
    3
    3
    3
    4
    30
    27
    60
    65
    46
    47
    3
    32
    Completed
    0
    0
    0
    2
    3
    0
    0
    0
    1
    2
    18
    7
    18
    8
    3
    7
    2
    6
    Not completed
    3
    3
    3
    10
    14
    3
    3
    3
    2
    2
    12
    20
    42
    57
    43
    40
    1
    26
         Death
    3
    2
    3
    6
    9
    3
    2
    3
    2
    2
    8
    13
    25
    46
    37
    22
    1
    17
         Study terminated by sponsor
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    1
    -
    -
    -
    -
         Unspecified
    -
    1
    -
    1
    1
    -
    1
    -
    -
    -
    2
    3
    8
    2
    2
    3
    -
    2
         Subject refused further follow-up
    -
    -
    -
    2
    3
    -
    -
    -
    -
    -
    1
    4
    7
    8
    3
    11
    -
    6
         Lost to follow-up
    -
    -
    -
    1
    1
    -
    -
    -
    -
    -
    1
    -
    2
    -
    1
    4
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    10 mg QD (Phase 1)
    Reporting group description
    PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    25 mg QD (Phase 1)
    Reporting group description
    PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.

    Reporting group title
    50 mg QD (Phase 1)
    Reporting group description
    PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    75 mg QD (Phase 1)
    Reporting group description
    PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    100 mg QD (Phase 1)
    Reporting group description
    PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    150 mg QD (Phase 1)
    Reporting group description
    PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.

    Reporting group title
    200 mg QD (Phase 1)
    Reporting group description
    PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    35 mg BID (Phase 1)
    Reporting group description
    PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    75 mg BID (Phase 1)
    Reporting group description
    PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    100 mg BID (Phase 1)
    Reporting group description
    PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-1 (Phase 2)
    Reporting group description
    Treatment-naïve participants with advanced ALK-positive NSCLC with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-2 (Phase 2)
    Reporting group description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-3 (Phase 2)
    Reporting group description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-4 (Phase 2)
    Reporting group description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-5 (Phase 2)
    Reporting group description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-6 (Phase 2)
    Reporting group description
    Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    Japan Lead-In Cohort (LIC)
    Reporting group description
    Few Japanese participants were given PF-06463922 100 mg orally once daily (QD) in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal to evaluate safety of PF-06463922 in Japanese participants, in order to support inclusion of Japanese participants in Phase 2.

    Reporting group title
    DDI Substudy
    Reporting group description
    Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1.

    Reporting group values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) Japan Lead-In Cohort (LIC) DDI Substudy Total
    Number of subjects
    3 3 3 12 17 3 3 3 3 4 30 27 60 65 46 47 3 32 364
    Age Categorical
    Units: Participants
        <18 years
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
        18-44 years
    0 1 0 5 7 1 1 0 0 2 4 5 14 19 13 12 2 5 91
        45-64 years
    1 1 3 6 9 1 2 2 2 1 18 13 34 37 26 27 1 20 204
        >=65 years
    2 1 0 1 1 1 0 1 1 1 8 9 12 9 7 8 0 7 69
    Sex: Female, Male
    Units: Participants
        Female
    2 0 1 7 11 2 2 2 3 2 13 17 38 37 25 27 2 15 206
        Male
    1 3 2 5 6 1 1 1 0 2 17 10 22 28 21 20 1 17 158
    Race/Ethnicity, Customized
    Units: Subjects
        WHITE
    2 2 3 7 13 2 2 1 2 3 10 13 25 32 27 25 0 21 190
        BLACK
    1 0 0 0 0 1 0 1 0 0 1 0 1 0 0 1 0 0 6
        ASIAN
    0 1 0 3 2 0 1 0 0 0 17 10 23 23 14 16 3 11 124
        OTHER
    0 0 0 0 1 0 0 0 0 0 1 2 1 3 2 3 0 0 13
        UNSPECIFIED
    0 0 0 2 1 0 0 1 1 1 1 2 10 7 3 2 0 0 31

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    10 mg QD (Phase 1)
    Reporting group description
    PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    25 mg QD (Phase 1)
    Reporting group description
    PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.

    Reporting group title
    50 mg QD (Phase 1)
    Reporting group description
    PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    75 mg QD (Phase 1)
    Reporting group description
    PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    100 mg QD (Phase 1)
    Reporting group description
    PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    150 mg QD (Phase 1)
    Reporting group description
    PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.

    Reporting group title
    200 mg QD (Phase 1)
    Reporting group description
    PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    35 mg BID (Phase 1)
    Reporting group description
    PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    75 mg BID (Phase 1)
    Reporting group description
    PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    100 mg BID (Phase 1)
    Reporting group description
    PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-1 (Phase 2)
    Reporting group description
    Treatment-naïve participants with advanced ALK-positive NSCLC with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-2 (Phase 2)
    Reporting group description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-3 (Phase 2)
    Reporting group description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-4 (Phase 2)
    Reporting group description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-5 (Phase 2)
    Reporting group description
    Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    EXP-6 (Phase 2)
    Reporting group description
    Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    Japan Lead-In Cohort (LIC)
    Reporting group description
    Few Japanese participants were given PF-06463922 100 mg orally once daily (QD) in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal to evaluate safety of PF-06463922 in Japanese participants, in order to support inclusion of Japanese participants in Phase 2.

    Reporting group title
    DDI Substudy
    Reporting group description
    Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1.

    Subject analysis set title
    ALK Positive Population (Phase 1)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.

    Subject analysis set title
    ROS1 Positive Population (Phase 1)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement.

    Subject analysis set title
    ALK Positive Population (Phase 1)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.

    Subject analysis set title
    ROS1 Positive Population (Phase 1)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement.

    Subject analysis set title
    Phase 1 ITT Population
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This reporting group includes all Phase 1 participants in the ITT analysis set.

    Subject analysis set title
    ALK Positive Population (Phase 1)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.

    Subject analysis set title
    Phase 1 PRO Evaluable Population
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This reporting group includes all Phase 1 participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment.

    Subject analysis set title
    Phase 2 ITT Population
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This reporting group includes all Phase 2 participants in the ITT analysis set.

    Subject analysis set title
    Phase 2 and Japan LIC PK Analysis Set
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data.

    Subject analysis set title
    Phase 2 and Japan LIC PK Analysis Set
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data.

    Subject analysis set title
    Phase 2 and Japan LIC PK Analysis Set
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data.

    Subject analysis set title
    Phase 2 and Japan LIC PK Analysis Set
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data.

    Subject analysis set title
    Phase 2
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Primary: Number of Participants with Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1

    Close Top of page
    End point title
    Number of Participants with Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 [1] [2]
    End point description
    DLT: any of following AEs:hematologic: grade (G)4 neutropenia for >7 days; febrile neutropenia; grade >=3 neutropenic infection; grade >=3 thrombocytopenia with bleeding; G4 thrombocytopenia; non-hematologic: grade >=3 pancreatitis; grade >=3 toxicities (excluding grade >=3 laboratory abnormalities not requiring dose modifications) persisting after optimal treatment with standard medical therapy; symptomatic grade >=3 QTc prolongation, or asymptomatic grade >=3 prolongation confirmed by repeat testing, persisted after correction of reversible causes; >=20% decrease from baseline in left ventricular ejection fraction (LVEF); other: failure to deliver at least 16 out of 21 prescribed daily total doses due to toxicite; failure to restart dosing after 21 days (1 cycle) delay due to toxicity. MTD evaluable population: all enrolled participants who received at least 75% of planned PF-06463922 dose in Cycle 1 and who received <75% of planned PF-06463922 doses in Cycle 1 due to DLT.
    End point type
    Primary
    End point timeframe
    Cycle 1 (21 days)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was planned
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    3
    3
    3
    11
    16
    3
    3
    2
    3
    3
    Units: Participants
        With DLT
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
        No DLT
    3
    2
    3
    6
    8
    2
    1
    2
    3
    2
        Data missing
    0
    1
    0
    5
    8
    1
    1
    0
    0
    1
    No statistical analyses for this end point

    Primary: Percentage of Participants with Overall and Intracranial Objective Response (Phase 2)

    Close Top of page
    End point title
    Percentage of Participants with Overall and Intracranial Objective Response (Phase 2) [3] [4]
    End point description
    Objective response (OR): confirmed CR or PR according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR: confirmed CR or PR considering only lesions within brain. CR: disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to <10 mm. PR:30% or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.ITT analysis set: all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with central nervous system (CNS) metastases in ITT analysis set were used for intracranial response assessment. "Number Analyzed": participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    3 years
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was planned
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2)
    Number of subjects analysed
    30
    27
    60
    65
    46
    47
    Units: Percentage of participants
    number (confidence interval 95%)
        OR, n=30,27,59,65,46, 47,32
    90.0 (73.5 to 97.9)
    74.1 (53.7 to 88.9)
    50.8 (37.5 to 64.1)
    41.5 (29.4 to 54.4)
    34.8 (21.4 to 50.2)
    36.2 (22.7 to 51.5)
        Intracranial OR,n=8,17,32,45,38, 25
    75.0 (34.9 to 96.8)
    58.8 (32.9 to 81.6)
    62.5 (43.7 to 78.9)
    55.6 (40.0 to 70.4)
    39.5 (24.0 to 56.6)
    56.0 (34.9 to 75.6)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)

    Close Top of page
    End point title
    Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)
    End point description
    Objective response (OR) refers to confirmed CR or PR according to RECIST version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to <10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.The ITT analysis set was used for overall response assessment and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with CNS metastases in the ITT analysis set was used for intracranial response assessment. Here, "Number Analyzed" signifies participants analyzed for this outcome measure.
    End point type
    Secondary
    End point timeframe
    From start of study treatment until CR or PR (maximum of 96.58 months of treatment exposure)
    End point values
    ALK Positive Population (Phase 1) ROS1 Positive Population (Phase 1)
    Number of subjects analysed
    41
    12
    Units: Percentage of participants
    number (confidence interval 95%)
        OR, n= 41, 12
    39.0 (24.2 to 55.5)
    50.0 (21.1 to 78.9)
        Intracranial OR, n=34, 8
    41.2 (24.6 to 59.3)
    50.0 (15.7 to 84.3)
    No statistical analyses for this end point

    Secondary: Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)

    Close Top of page
    End point title
    Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)
    End point description
    TTR: time from first dose of study treatment to first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, onset of PR was taken as onset of response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to <10 mm. PR: 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. TTR was calculated for subgroup of participants with confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial OR. Results presented here were based on independent central review.TTR analysis set:all ITT participants who had confirmed objective response; intracranial TTR analysis set:all ITT participants who had CNS metastases and achieved confirmed intracranial objective response
    End point type
    Secondary
    End point timeframe
    From start of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 96.58 months of treatment exposure)
    End point values
    ALK Positive Population (Phase 1) ROS1 Positive Population (Phase 1)
    Number of subjects analysed
    16
    6
    Units: Months
    median (full range (min-max))
        TTR, n=16, 6
    1.4 (1.2 to 15.2)
    1.4 (1.2 to 2.8)
        Intracranial TTR, n=14, 4
    1.4 (1.2 to 20.1)
    1.4 (1.1 to 2.8)
    No statistical analyses for this end point

    Secondary: Number of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1)

    Close Top of page
    End point title
    Number of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1)
    End point description
    DOR: time from first documentation of objective tumor response (CR/PR) to first documentation of disease progression (PD) or death due to any cause. Intracranial DOR:calculated for participants with confirmed intracranial (IC) OR. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Pathological lymph node (recorded as target lesion) must have reduction in short axis to <10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in SLD of target lesion relative to baseline/smallest SLD (nadir) recorded since first dose,demonstrate absolute increase of atleast 5mm(>=5mm) relative to baseline/smallest SLD recorded since first dose.DOR analysis set: ITT participant who had confirmed OR; IC DOR set: ITT participant who had CNS metastases, achieved confirmed IC OR.99999:Number of participant with confirmed OR was too small to provide summary statistics.
    End point type
    Secondary
    End point timeframe
    From start of study treatment to first documentation of disease progression (PD) or to death due to any cause, whichever occurred first (maximum of 96.58 months of treatment exposure)
    End point values
    ALK Positive Population (Phase 1) ROS1 Positive Population (Phase 1)
    Number of subjects analysed
    16
    6
    Units: Participants
    number (not applicable)
        DOR, <3 Months, n=16,6
    1
    0
        DOR,3 Months < 6 Months, n=16,6
    6
    0
        DOR, 6 Months -< 9 Months, n=16,6
    0
    1
        DOR, 9 Months -< 12 Months, n=16,6
    0
    1
        DOR,12 Months -< 15 Months, n=16,6
    1
    0
        DOR, 15 Months -< 18 Months, n=16,6
    0
    0
        DOR, 18 Months -< 21 Months, n=16, 6
    0
    0
        DOR, 21 Months -< 24 Months, n=16, 6
    1
    0
        DOR,>= 24 Months, n=16, 6
    1
    2
        Intracranial DOR, <3 Months, n=14, 4
    1
    0
        Intracranial DOR, 3 Months < 6 Months, n=14, 4
    0
    0
        Intracranial DOR, 6 Months -< 9 Months, n=14, 4
    1
    0
        Intracranial DOR, 9 Months -< 12 Months, n=14, 4
    0
    0
        Intracranial DOR, 12 Months -< 15 Months, n=14, 4
    1
    0
        Intracranial DOR, 15 Months -< 18 Months, n=14, 4
    0
    0
        Intracranial DOR, 18 Months -< 21 Months, n=14, 4
    0
    0
        Intracranial DOR, 21 Months -< 24 Months, n=14, 4
    0
    0
        Intracranial DOR, >= 24 Months, n=14, 4
    0
    0
    No statistical analyses for this end point

    Secondary: Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1)

    Close Top of page
    End point title
    Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1)
    End point description
    Tumor response was evaluated as per to RECIST v1.1, disease control: confirmed CR, confirmed PR, or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to <10 mm. PR: 30% or more decrease in SLD of target lesion, taking as reference baseline SLD. Progressive disease: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must demonstrate absolute increase of atleast 5mm (>=5mm) relative to baseline or smallest SLD (nadir). ITT analysis set: all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with CNS metastases in ITT analysis set was used for intracranial response assessment.
    End point type
    Secondary
    End point timeframe
    12 and 24 weeks
    End point values
    ALK Positive Population (Phase 1) ROS1 Positive Population (Phase 1)
    Number of subjects analysed
    41
    12
    Units: Percentage of participants
    number (confidence interval 95%)
        DCR at Week 12, n=41,12
    53.7 (37.4 to 69.3)
    58.3 (27.7 to 84.8)
        DCR at Week 24, n=41,12
    39.0 (24.2 to 55.5)
    50.0 (21.1 to 78.9)
        Intracranial DCR at Week 12, n=34, 8
    50.0 (32.4 to 67.6)
    37.5 (8.5 to 75.5)
        Intracranial DCR at Week 24, n=34, 8
    41.2 (24.6 to 59.3)
    37.5 (8.5 to 75.5)
    No statistical analyses for this end point

    Secondary: Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)

    Close Top of page
    End point title
    Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)
    End point description
    Probability of first event being a CNS progression, a non-CNS progression, or death was evaluated with a competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to the analysis set. The time to first event being a Competing Event (either “CNS progression” or “non CNS progression” or “Death”) was defined as time from first dose until the date of that specific event. Participants not known to have any of the Competing Events were censored on the date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as a competing cause of failure for the analysis of other type of events. For each type of event, the cumulative incidence function corresponding to the nearest time point preceding 1 year is presented. Results are based on independent central review. intent-to-treat (ITT) analysis set: all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922.
    End point type
    Secondary
    End point timeframe
    From start of study treatment until first event of CNS progression (maximum of 96.58 months of treatment exposure)
    End point values
    Phase 1 ITT Population
    Number of subjects analysed
    53
    Units: Probability of events
    number (not applicable)
        CNS progression
    0.260
        Non CNS progression
    0.352
        Death
    0.060
    No statistical analyses for this end point

    Secondary: Progression-Free Survival (PFS) (Phase 1)

    Close Top of page
    End point title
    Progression-Free Survival (PFS) (Phase 1)
    End point description
    PFS was defined as the time from the first dose of study treatment to the first documentation of objective disease progression or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review. PFS analysis set included all participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922.
    End point type
    Secondary
    End point timeframe
    From start of study treatment to first documentation of disease progression (PD) or to death due to any cause, whichever occurred first (maximum of 96.58 months of treatment exposure)
    End point values
    ALK Positive Population (Phase 1) ROS1 Positive Population (Phase 1)
    Number of subjects analysed
    41
    12
    Units: Months
        median (confidence interval 95%)
    5.4 (2.7 to 11.8)
    10.1 (1.6 to 33.0)
    No statistical analyses for this end point

    Secondary: Overall Survival (OS) (Phase 1)

    Close Top of page
    End point title
    Overall Survival (OS) (Phase 1)
    End point description
    OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method. ITT analysis set: all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922."Number Analyzed": participants analyzed for this outcome measure. 99999 represents “A large proportion of participants in the analysis set had their OS data censored, and number of participants dead by the cutoff date of this report was small, so it's impossible to derive such summary statistics.”
    End point type
    Secondary
    End point timeframe
    3 years
    End point values
    ALK Positive Population (Phase 1) ROS1 Positive Population (Phase 1)
    Number of subjects analysed
    41
    12
    Units: Months
        median (confidence interval 95%)
    22.3 (11.4 to 99999)
    99999 (4.7 to 99999)
    No statistical analyses for this end point

    Secondary: Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)

    Close Top of page
    End point title
    Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1) [5]
    End point description
    Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. 99999 represents “Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 390 and 423 ng/mL, respectively.”
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
    Notes
    [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    3
    3
    2
    12
    16
    3
    3
    3
    3
    4
    Units: Nanograms per milliliter (ng/mL)
        geometric mean (geometric coefficient of variation)
    50.80 ( 17 )
    149.2 ( 71 )
    99999 ( 99999 )
    489.1 ( 45 )
    595.5 ( 37 )
    760.0 ( 58 )
    1201 ( 19 )
    202.2 ( 57 )
    594.9 ( 27 )
    507.2 ( 51 )
    No statistical analyses for this end point

    Secondary: Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Close Top of page
    End point title
    Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1) [6]
    End point description
    Maximum Observed Plasma Concentration (Cmax) of PF-06463922 was observed directly from data. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. 99999 represents “Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 760 and 1430 ng/mL, respectively.” and “when fewer than 3 participants had reportable values. The individual value is 370 ng/mL”
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).
    Notes
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    3
    3
    3
    12
    16
    3
    3
    3
    3
    3
    Units: ng/mL
        geometric mean (geometric coefficient of variation)
    67.29 ( 18 )
    138.1 ( 35 )
    359.7 ( 27 )
    429.6 ( 48 )
    550.2 ( 32 )
    541.0 ( 42 )
    99999 ( 99999 )
    99999 ( 99999 )
    550.0 ( 23 )
    600.5 ( 27 )
    No statistical analyses for this end point

    Secondary: Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)

    Close Top of page
    End point title
    Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1) [7]
    End point description
    Tmax of PF-06463922 was observed directly from data as time of first occurrence. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
    Notes
    [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    3
    3
    2
    12
    16
    3
    3
    3
    3
    4
    Units: Hours
        median (full range (min-max))
    1.98 (1.00 to 2.97)
    2.00 (0.50 to 2.05)
    1.25 (0.50 to 2.00)
    1.09 (0.50 to 4.03)
    1.96 (0.517 to 4.33)
    1.05 (1.00 to 3.00)
    2.00 (1.18 to 3.00)
    1.20 (0.50 to 1.97)
    1.23 (1.00 to 2.00)
    2.00 (1.10 to 3.07)
    No statistical analyses for this end point

    Secondary: Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Close Top of page
    End point title
    Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1) [8]
    End point description
    Tmax of PF-06463922 was observed directly from data as time of first occurrence. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).
    Notes
    [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    3
    3
    3
    12
    16
    3
    3
    3
    3
    3
    Units: Hours
        median (full range (min-max))
    1.00 (1.00 to 1.08)
    1.00 (1.00 to 2.00)
    2.00 (1.92 to 2.75)
    1.03 (0.50 to 2.00)
    1.13 (1.00 to 4.00)
    1.30 (1.00 to 24.0)
    1.61 (1.22 to 2.00)
    0.50 (0.50 to 0.50)
    0.55 (0.50 to 2.05)
    2.00 (1.00 to 2.00)
    No statistical analyses for this end point

    Secondary: Area under the Plasma Concentration-Time profile from Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)

    Close Top of page
    End point title
    Area under the Plasma Concentration-Time profile from Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1) [9]
    End point description
    Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. 99999 represents “Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 3310 and 3880 ng*hr/mL, respectively.”
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours post-dose on Day -7 for all other groups.
    Notes
    [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    3
    3
    2
    12
    16
    3
    3
    3
    3
    4
    Units: Nanogram*hour/milliliter (ng*hr/mL)
        geometric mean (geometric coefficient of variation)
    488.2 ( 21 )
    1387 ( 35 )
    99999 ( 99999 )
    3990 ( 55 )
    5110 ( 28 )
    7474 ( 73 )
    11410 ( 43 )
    982.4 ( 9 )
    2996 ( 20 )
    2925 ( 47 )
    No statistical analyses for this end point

    Secondary: Area under the Plasma Concentration-Time profile from Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Close Top of page
    End point title
    Area under the Plasma Concentration-Time profile from Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1) [10]
    End point description
    Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. 99999 represents “Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 4480 and 12900 ng*hr/mL, respectively and when fewer than 3 participants had reportable values. The individual value is 2140 ng*hr/mL.”
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
    Notes
    [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    3
    3
    3
    12
    16
    3
    2
    1
    3
    3
    Units: ng*hr/mL
        geometric mean (geometric coefficient of variation)
    752.1 ( 26 )
    1701 ( 29 )
    3367 ( 39 )
    4107 ( 53 )
    5121 ( 30 )
    6157 ( 9 )
    99999 ( 99999 )
    99999 ( 99999 )
    3574 ( 35 )
    4058 ( 33 )
    No statistical analyses for this end point

    Secondary: Area under the Plasma Concentration-Time Profile from Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)

    Close Top of page
    End point title
    Area under the Plasma Concentration-Time Profile from Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1) [11]
    End point description
    AUCinf was calculated as AUClast+(Clast*/kel),where AUClast was area under plasma concentration-time profile from time 0 to time of last quantifiable concentration,Clast* was predicted plasma concentration at last quantifiable time point estimated from log-linear regression analysis, kel was rate constant for terminal phase.PK parameter analysis set for PF-06463922:all enrolled participants who received at least 1 dose of PF-06463922,had sufficient information to estimate at least one of PK parameter.Overall Number of Participants Analyzed: participants evaluable for this outcome measure.99999:Summary statistics were not calculated when fewer than 3 participants had reportable value.Individual value:698 ng*hr/mL;when fewer than 3 participant had reportable value.Individual values are 7210 and 7240 ng*hr/mL; when fewer than 3 participant had reportable value.Individual values are 2630 and 3690 ng*hr/mL. when fewer than 3 participant had reportable value.Individual value:6860 ng*hr/mL.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
    Notes
    [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    1
    2
    11
    15
    3
    2
    1
    4
    Units: ng*hr/mL
        geometric mean (geometric coefficient of variation)
    99999 ( 99999 )
    99999 ( 99999 )
    7663 ( 79 )
    8236 ( 25 )
    18340 ( 61 )
    99999 ( 99999 )
    99999 ( 99999 )
    6318 ( 56 )
    No statistical analyses for this end point

    Secondary: Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)

    Close Top of page
    End point title
    Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1) [12]
    End point description
    Clearance of drug is measure of rate at which drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was area under plasma concentration-time profile from time 0 extrapolated to infinite time. PK parameter analysis set for PF-06463922: all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of PK parameters of interest for PF-06463922.Overall Number of Participants Analyzed: participants evaluable for this outcome measure. Summary statistics were not calculated when fewer than 3 participants had reportable values. individual value is 14.3 L/hr; when fewer than 3 participants had reportable values. Individual values are 6.91 and 6.94 L/hr, respectively; when fewer than 3 participants had reportable values. Individual values are 9.48 and 13.3 L/hr, respectively; when fewer than 3 participants had reportable values. The individual value is 10.9 L/hr.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
    Notes
    [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    1
    2
    11
    15
    3
    2
    1
    4
    Units: Liter/hour (L/hr)
        geometric mean (geometric coefficient of variation)
    99999 ( 99999 )
    99999 ( 99999 )
    9.788 ( 79 )
    12.14 ( 25 )
    10.90 ( 61 )
    99999 ( 99999 )
    99999 ( 99999 )
    15.83 ( 56 )
    No statistical analyses for this end point

    Secondary: Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Close Top of page
    End point title
    Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1) [13]
    End point description
    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. 99999: Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 15.5 and 44.6 L/hr, respectively and when fewer than 3 participants had reportable values. The individual value is 16.3 L/hr.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
    Notes
    [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    3
    3
    3
    12
    16
    3
    2
    1
    3
    3
    Units: L/hr
        geometric mean (geometric coefficient of variation)
    13.27 ( 26 )
    14.72 ( 29 )
    14.84 ( 39 )
    17.66 ( 48 )
    19.52 ( 30 )
    24.37 ( 9 )
    99999 ( 99999 )
    99999 ( 99999 )
    20.99 ( 35 )
    22.37 ( 47 )
    No statistical analyses for this end point

    Secondary: Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)

    Close Top of page
    End point title
    Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1) [14]
    End point description
    Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase. Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 373 L; when fewer than 3 participants had reportable values. Individual values are 166 and 307 L, respectively; when fewer than 3 participants had reportable values. Individual values are 362 and 472 L, respectively. Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 410 L.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
    Notes
    [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    1
    2
    11
    15
    3
    2
    1
    4
    Units: Liters (L)
        geometric mean (geometric coefficient of variation)
    99999 ( 99999 )
    99999 ( 99999 )
    367.9 ( 54 )
    356.3 ( 39 )
    307.8 ( 41 )
    99999 ( 99999 )
    99999 ( 99999 )
    378.3 ( 54 )
    No statistical analyses for this end point

    Secondary: Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Close Top of page
    End point title
    Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1) [15]
    End point description
    Rac was calculated as Day 15 AUCtau/Day -7 AUCtau or Day 1 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively). PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.Standard deviation was not calculated when fewer than 3 participants had reportable values and when fewer than 3 participants had reportable values. The individual value is 2.09.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
    Notes
    [15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    3
    3
    2
    12
    15
    3
    2
    1
    3
    3
    Units: Ratio
        arithmetic mean (standard deviation)
    1.543 ( 0.075056 )
    1.237 ( 0.20817 )
    1.105 ( 99999 )
    1.121 ( 0.44575 )
    1.071 ( 0.31138 )
    1.000 ( 0.79137 )
    0.6500 ( 99999 )
    99999 ( 99999 )
    1.231 ( 0.35228 )
    1.523 ( 0.29569 )
    No statistical analyses for this end point

    Secondary: Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)

    Close Top of page
    End point title
    Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1) [16]
    End point description
    Terminal plasma half-life: time measured for plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was rate constant for terminal phase. PK parameter analysis set for PF-06463922: all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of PK parameters of interest for PF-06463922. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. 99999: Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual value is 18.0 hr; when fewer than 3 participants had reportable values. Individual values are 16.6 and 30.8 hr, respectively; Standard deviation was not calculated when fewer than 3 participants had reportable values. Individual values are 24.6 and 26.5 hr, respectively; Summary statistics were not calculated when fewer than 3 participants had reportable values. individual value is 26.0 hr.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
    Notes
    [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    1
    2
    11
    15
    3
    2
    1
    4
    Units: Hours (hr)
        arithmetic mean (standard deviation)
    99999 ( 99999 )
    23.70 ( 99999 )
    27.22 ( 8.2961 )
    20.89 ( 5.0308 )
    19.80 ( 3.3045 )
    25.55 ( 99999 )
    99999 ( 99999 )
    17.18 ( 5.1874 )
    No statistical analyses for this end point

    Secondary: Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Close Top of page
    End point title
    Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1) [17]
    End point description
    Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was area under plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively).PK parameter analysis set for PF-06463922: all enrolled participants who received at least 1 dose of PF-06463922, had sufficient information to estimate at least one of PK parameters of interest. Overall Number of Participants Analyzed: participants evaluable for this outcome measure. 99999: summary statistics were not calculated when fewer than 3 participants had reportable values,individual value:0.993; SD was not calculated when fewer than 3 participants had reportable values. Individual values:0.401 and 0.719,when fewer than 3 participants had reportable values. Individual values:0.384 and 0.403, summary statistics were not calculated when fewer than 3 participants had reportable values. individual value:0.815; fewer than 3 participants had reportable values. individual value:0.542.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
    Notes
    [17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    1
    2
    11
    14
    2
    1
    1
    3
    Units: Ratio
        arithmetic mean (standard deviation)
    99999 ( 99999 )
    0.5600 ( 99999 )
    0.6131 ( 0.29021 )
    0.6603 ( 0.18604 )
    0.3935 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    0.7687 ( 0.13552 )
    No statistical analyses for this end point

    Secondary: Renal Clearance (CLr) of PF-06463922 (Phase 1)

    Close Top of page
    End point title
    Renal Clearance (CLr) of PF-06463922 (Phase 1) [18]
    End point description
    Renal clearance was calculated as Aetau/AUCtau, where Aetau was cumulative amount of drug recovered unchanged in urine up to dosing interval tau (24 hours for QD dosing regimen), and AUCtau was area under plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen). PK parameter analysis set for PF-06463922: all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of PK parameters of interest for PF-06463922. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15
    Notes
    [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    100 mg QD (Phase 1)
    Number of subjects analysed
    3
    Units: ml/hour
        geometric mean (geometric coefficient of variation)
    61.31 ( 58 )
    No statistical analyses for this end point

    Secondary: Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)

    Close Top of page
    End point title
    Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1) [19]
    End point description
    Dosing interval was 24 hours for QD dosing regimen. Aetau% was calculated as 100*Ae24/dose, where Ae24 was the cumulative amount of drug recovered unchanged in urine up to 24 hours post-dose. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. As planned, this parameter was only analyzed for 100 mg QD group. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15
    Notes
    [19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    100 mg QD (Phase 1)
    Number of subjects analysed
    3
    Units: Percentage of recovered PF-06463922
        arithmetic mean (standard deviation)
    0.4017 ( 0.11074 )
    No statistical analyses for this end point

    Secondary: Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)

    Close Top of page
    End point title
    Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1) [20]
    End point description
    Cmax of midazolam was observed directly from data. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflected the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflected the PK assessment after multiple doses of PF-06463922 were administered. PK parameter analysis set for PF-06463922: all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    Notes
    [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    25 mg QD (Phase 1) 150 mg QD (Phase 1)
    Number of subjects analysed
    3
    3
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Day -7
    16.06 ( 42 )
    11.56 ( 48 )
        Cycle 1 Day 15
    9.697 ( 40 )
    5.734 ( 43 )
    No statistical analyses for this end point

    Secondary: Time for Cmax (Tmax) of Midazolam (Phase 1)

    Close Top of page
    End point title
    Time for Cmax (Tmax) of Midazolam (Phase 1) [21]
    End point description
    Tmax of midazolam was observed directly from data as time of first occurrence. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered. PK parameter analysis set for midazolam: all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    Notes
    [21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    25 mg QD (Phase 1) 150 mg QD (Phase 1)
    Number of subjects analysed
    3
    3
    Units: Hours
    median (full range (min-max))
        Day -7
    0.50 (0.50 to 1.00)
    0.50 (0.50 to 0.50)
        Cycle 1 Day 15
    0.50 (0.50 to 1.00)
    0.50 (0.50 to 0.533)
    No statistical analyses for this end point

    Secondary: Area under the Plasma Concentration-Time profile from Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)

    Close Top of page
    End point title
    Area under the Plasma Concentration-Time profile from Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1) [22]
    End point description
    Area under plasma concentration-time profile from time 0 to time of last quantifiable concentration (AUClast) of midazolam was determined using linear/log trapezoidal method. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect PK assessment after multiple doses of PF-06463922 were administered. PK parameter analysis set for midazolam: all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    Notes
    [22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    25 mg QD (Phase 1) 150 mg QD (Phase 1)
    Number of subjects analysed
    3
    3
    Units: ng*hr/mL
    geometric mean (geometric coefficient of variation)
        Day -7
    51.30 ( 47 )
    36.49 ( 20 )
        Cycle 1 Day 15
    20.43 ( 18 )
    14.44 ( 25 )
    No statistical analyses for this end point

    Secondary: Area under the Plasma Concentration-Time Profile from Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)

    Close Top of page
    End point title
    Area under the Plasma Concentration-Time Profile from Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1) [23]
    End point description
    AUCinf was calculated as AUClast + (Clast*/kel), where AUClast was area under plasma concentration-time profile from time 0 to time of last quantifiable concentration, Clast* was predicted plasma concentration at last quantifiable time point estimated from the log-linear regression analysis, and kel was rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect PK assessment after multiple doses of PF-06463922 were administered. PK parameter analysis set for midazolam: all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available. 99999: Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 42.2 and 46.8 ng*hr/mL, respectively.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    Notes
    [23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    25 mg QD (Phase 1) 150 mg QD (Phase 1)
    Number of subjects analysed
    3
    3
    Units: ng*hr/mL
    geometric mean (geometric coefficient of variation)
        Day -7, n=3, 2
    54.53 ( 43 )
    99999 ( 99999 )
        Cycle 1 Day 15, n=3 ,3
    21.32 ( 18 )
    16.09 ( 29 )
    No statistical analyses for this end point

    Secondary: Apparent Oral Clearance (CL/F) of Midazolam (Phase 1)

    Close Top of page
    End point title
    Apparent Oral Clearance (CL/F) of Midazolam (Phase 1) [24]
    End point description
    Clearance of drug is measure of rate at which drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was area under plasma concentration-time profile from time 0 extrapolated to infinite time. Only participants in 25 and 150 mg QD groups were given midazolam. Day -7 data reflect PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect PK assessment after multiple doses of PF-06463922 were administered.PK parameter analysis set: all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available.Number Analyzed:participants evaluable for specified rows.99999: Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 42.7 and 47.4 L/hr.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    Notes
    [24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    25 mg QD (Phase 1) 150 mg QD (Phase 1)
    Number of subjects analysed
    3
    3
    Units: L/hr
    geometric mean (geometric coefficient of variation)
        Day -7, n=3, 2
    36.68 ( 43 )
    99999 ( 99999 )
        Cycle 1 Day 15, n=3, 3
    93.86 ( 18 )
    124.2 ( 29 )
    No statistical analyses for this end point

    Secondary: Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)

    Close Top of page
    End point title
    Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1) [25]
    End point description
    Vz/F was defined as theoretical volume in which total amount of drug would need to be uniformly distributed to produce desired plasma concentration of drug, and calculated as dose/(AUCinf*kel), where AUCinf was area under plasma concentration-time profile from time 0 extrapolated to infinite time, kel was rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect PK assessment after multiple doses of PF-06463922 were administered. PK parameter analysis set for midazolam: all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available. Here, 'Number Analyzed' signifies participants evaluable for specified rows. 99999:Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 161 and 486 L, respectively
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    Notes
    [25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    25 mg QD (Phase 1) 150 mg QD (Phase 1)
    Number of subjects analysed
    3
    3
    Units: Liters
    geometric mean (geometric coefficient of variation)
        Day -7, n=3, 2
    229.0 ( 7 )
    99999 ( 99999 )
        Cycle 1 Day 15, n=3, 3
    404.4 ( 51 )
    702.2 ( 100 )
    No statistical analyses for this end point

    Secondary: Terminal Half-Life of Midazolam (Phase 1)

    Close Top of page
    End point title
    Terminal Half-Life of Midazolam (Phase 1) [26]
    End point description
    Terminal plasma half-life was defined as time measured for plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect PK assessment after multiple doses of PF-06463922 were administered. PK parameter analysis set for midazolam: all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available. Here, 'Number Analyzed' signifies participants evaluable for specified rows.99999 represents “Standard deviation was not calculated when fewer than 3 participants had reportable values. Individual values are 2.35 and 7.89 hr, respectively”
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    Notes
    [26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    25 mg QD (Phase 1) 150 mg QD (Phase 1)
    Number of subjects analysed
    3
    3
    Units: Hour
    arithmetic mean (standard deviation)
        Day -7, n=3, 2
    4.620 ( 1.9328 )
    5.120 ( 99999 )
        Cycle 1 Day 15, n=3, 3
    3.343 ( 2.0358 )
    5.257 ( 5.0639 )
    No statistical analyses for this end point

    Secondary: Number of Participants with ALK Mutation Based on Plasma CNA Analysis (Phase 1)

    Close Top of page
    End point title
    Number of Participants with ALK Mutation Based on Plasma CNA Analysis (Phase 1)
    End point description
    Plasma circulating nucleic acid (CNA) samples were analyzed for ALK kinase domain mutations by digital polymerase chain reaction (PCR) BEAMing technology. Number of participants with one or more ALK mutations is presented.
    End point type
    Secondary
    End point timeframe
    Screening (up to 28 days)
    End point values
    ALK Positive Population (Phase 1)
    Number of subjects analysed
    40
    Units: Participants
    14
    No statistical analyses for this end point

    Secondary: Number of Participants with ALK Mutation Based on Tumor Tissue Analysis (Phase 1)

    Close Top of page
    End point title
    Number of Participants with ALK Mutation Based on Tumor Tissue Analysis (Phase 1)
    End point description
    Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.
    End point type
    Secondary
    End point timeframe
    Screening (up to 28 days)
    End point values
    ALK Positive Population (Phase 1)
    Number of subjects analysed
    40
    Units: Participants
    7
    No statistical analyses for this end point

    Secondary: Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)

    Close Top of page
    End point title
    Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)
    End point description
    European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
    End point type
    Secondary
    End point timeframe
    From start of study treatment until end of treatment (maximum of 96.58 months of treatment exposure)
    End point values
    Phase 1 PRO Evaluable Population
    Number of subjects analysed
    43
    Units: participants
        Improved in global QoL
    19
        Stable in global QoL
    13
        Worsened in global QoL
    11
        Improved in physical functioning
    5
        Stable in physical functioning
    29
        Worsened in physical functioning
    9
        Improved in role functioning
    14
        Stable in role functioning
    15
        Worsened in role functioning
    14
        Improved in emotional functioning
    15
        Stable in emotional functioning
    21
        Worsened in emotional functioning
    7
        Improved in cognitive functioning
    8
        Stable in cognitive functioning
    21
        Worsened in cognitive functioning
    14
        Improved in social functioning
    13
        Stable in social functioning
    17
        Worsened in social functioning
    13
        Improved in fatigue
    17
        Stable in fatigue
    19
        Worsened in fatigue
    7
        Improved in nausea and vomiting
    10
        Stable in nausea and vomiting
    32
        worsened in nausea and vomiting
    1
        Improved in pain
    17
        Stable in pain
    16
        Worsened in pain
    10
        Improved in dyspnea
    13
        Stable in dyspnea
    19
        Worsened in dyspnea
    11
        Improved in insomnia
    19
        Stable in insomnia
    17
        Worsened in insomnia
    7
        Improved in appetite loss
    14
        Stable in appetite loss
    27
        Worsened in appetite loss
    2
        Improved in constipation
    10
        Stable in constipation
    28
        Worsened in constipation
    5
        Improved in diarrhea
    9
        Stable in diarrhea
    28
        Worsened in diarrhea
    6
        Improved in financial difficulties
    7
        Stable in financial difficulties
    20
        Worsened in financial difficulties
    16
    No statistical analyses for this end point

    Secondary: Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)

    Close Top of page
    End point title
    Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)
    End point description
    EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
    End point type
    Secondary
    End point timeframe
    From start of study treatment until end of treatment (maximum of 96.58 months of treatment exposure)
    End point values
    Phase 1 PRO Evaluable Population
    Number of subjects analysed
    43
    Units: Participants
        Improved in dyspnea
    9
        Stable in dyspnea
    23
        Worsened in dyspnea
    11
        Improved in coughing
    23
        Stable in coughing
    12
        Worsened in coughing
    8
        Improved in hemoptysis
    1
        Stable in hemoptysis
    42
        Worsened in hemoptysis
    0
        Improved in sore mouth
    0
        Stable in sore mouth
    40
        Worsened in sore mouth
    3
        Improved in dysphagia
    4
        Stable in dysphagia
    37
        Worsened in dysphagia
    2
        Improved in peripheral neuropathy
    6
        Stable in peripheral neuropathy
    21
        Worsened in peripheral neuropathy
    16
        Improved in alopecia
    4
        Stable in alopecia
    29
        Worsened in alopecia
    9
        Improved in chest pain
    16
        Stable in chest pain
    22
        Worsened in chest pain
    5
        Improved in arm or shoulder pain
    10
        Stable in arm or shoulder pain
    27
        Worsened in arm or shoulder pain
    6
        Improved in pain in other parts
    20
        Stable in pain in other parts
    12
        Worsened in pain in other parts
    11
    No statistical analyses for this end point

    Secondary: Change from Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)

    Close Top of page
    End point title
    Change from Baseline in Mini Mental State Examination (MMSE) Score (Phase 1) [27]
    End point description
    In Phase 1, MMSE was collected to assess mental status. MMSE is 30 item questionnaire that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall and language. Maximum score is 30 and minimum score is 0. Highest score indicates no cognitive impairment, lowest score indicates severe cognitive impairment. MMSE was removed under Amendment 6 of study protocol, and not required for Phase 2, as tool was not considered meaningful for assessment of cognitive function. MMSE assessment evaluable analysis set: all participants in safety analysis set (all participants who received at least 1 dose of PF-06463922) who completed baseline and at least 1 post-baseline assessment. Overall Number of Participants Analyzed: participants evaluable for this outcome measure. Number Analyzed: participants evaluable for specified rows. 99999:SD could not be calculated as only 1 participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 1 of Cycle 1-52, and end of treatment (up to 3 years)
    Notes
    [27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1)
    Number of subjects analysed
    2
    3
    3
    9
    16
    3
    2
    2
    3
    4
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Cycle 1 Day 1, n=2,0,2,7,9,0,0,0,1,1
    1.0 ( 1.41 )
    99999 ( 99999 )
    -0.5 ( 0.71 )
    -0.9 ( 2.27 )
    0.8 ( 1.39 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 99999 )
        Cycle 2 Day 1, n=1,3,1,9,16,3,2,2,2,3
    2.0 ( 99999 )
    -0.3 ( 0.58 )
    2.0 ( 99999 )
    0.3 ( 1.41 )
    0.0 ( 1.79 )
    4.7 ( 8.08 )
    4.0 ( 4.24 )
    0.0 ( 0.00 )
    0.0 ( 0.00 )
    -0.3 ( 1.15 )
        Cycle 3 Day 1,2,3,2,8,15,2,2,0,1,3
    2.0 ( 0.00 )
    0.3 ( 0.58 )
    -0.5 ( 0.71 )
    -0.6 ( 1.85 )
    0.2 ( 1.52 )
    5.0 ( 8.49 )
    3.0 ( 2.83 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -1.0 ( 1.00 )
        Cycle 4 Day 1, n=1,2,2,8,14,3,2,0,1,3
    5.0 ( 99999 )
    0.5 ( 0.71 )
    1.5 ( 2.12 )
    -1.1 ( 1.81 )
    0.0 ( 1.47 )
    2.0 ( 6.24 )
    -0.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.7 ( 1.15 )
        Cycle 5 Day 1, n=2,2,2,7,11,3,2,0,1,3
    0.5 ( 3.54 )
    0.5 ( 0.71 )
    1.5 ( 2.12 )
    0.3 ( 1.25 )
    -0.2 ( 1.72 )
    4.7 ( 8.14 )
    0.5 ( 6.36 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.5 ( 0.71 )
        Cycle 6 Day 1, =1,2,2,7,12,3,2,0,1,3
    2.5 ( 2.12 )
    0.5 ( 0.71 )
    1.0 ( 1.41 )
    -0.4 ( 2.70 )
    0.3 ( 0.90 )
    4.3 ( 5.86 )
    2.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -1.3 ( 2.31 )
        Cycle 7 Day 1, n=0,2,1,7,11,2,1,0,0,3
    2.0 ( 99999 )
    0.5 ( 0.71 )
    1.5 ( 2.12 )
    -0.1 ( 1.21 )
    0.4 ( 0.90 )
    4.7 ( 8.33 )
    3.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.7 ( 1.15 )
        Cycle 8 Day 1, n=1,2,1,5,10,2,1,0,1,3
    -4.0 ( 99999 )
    0.5 ( 0.71 )
    1.5 ( 2.12 )
    -0.1 ( 2.34 )
    0.2 ( 1.34 )
    3.0 ( 7.81 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 9 Day 1, n=0,2,1,7,11,2,1,0,0,3
    99999 ( 99999 )
    0.0 ( 0.00 )
    0.0 ( 99999 )
    -1.0 ( 2.31 )
    0.3 ( 2.10 )
    6.0 ( 8.49 )
    6.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    -0.3 ( 0.58 )
        Cycle 10 Day 1, n=1,2,1,5,10,2,1,0,1,3
    -5.0 ( 99999 )
    0.5 ( 0.71 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
    -0.1 ( 0.88 )
    6.5 ( 9.19 )
    6.0 ( 99999 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -1.7 ( 1.53 )
        Cycle 11 Day 1, n=0,2,1,7,12,2,2,0,1,3
    99999 ( 99999 )
    -0.5 ( 0.71 )
    0.0 ( 99999 )
    0.3 ( 1.70 )
    -0.2 ( 1.53 )
    7.0 ( 8.49 )
    3.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 12 Day 1, n=0,2,0,5,12,2,2,0,1,2
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    -0.6 ( 2.19 )
    -0.2 ( 2.33 )
    6.5 ( 9.19 )
    3.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.7 ( 0.58 )
        Cycle 13 Day 1, n=0,2,0,5,10,2,2,0,1,2
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    0.8 ( 1.79 )
    0.5 ( 2.22 )
    5.5 ( 7.78 )
    3.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.5 ( 0.71 )
        Cycle 14 Day 1, n=0,2,0,6,11,2,2,0,1,3
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    -0.3 ( 3.20 )
    0.3 ( 0.79 )
    6.0 ( 8.49 )
    2.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 15 Day 1, n=0,2,0,6,9,0,2,0,1,3
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    -1.7 ( 5.43 )
    0.1 ( 1.36 )
    99999 ( 99999 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.3 ( 0.58 )
        Cycle 16 Day 1, n=0,2,0,5,9,1,2,0,1,2
    99999 ( 99999 )
    0.0 ( 1.41 )
    99999 ( 99999 )
    -0.2 ( 2.49 )
    -0.2 ( 1.99 )
    1.0 ( 99999 )
    1.5 ( 6.36 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 17 Day 1, n=0,2,0,5,9,1,2,0,1,3
    99999 ( 99999 )
    -2.0 ( 2.83 )
    99999 ( 99999 )
    0.6 ( 1.95 )
    0.1 ( 1.17 )
    -3.0 ( 99999 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -1.3 ( 1.53 )
        Cycle 18 Day 1, n=0,2,0,5,9,1,2,0,0,2
    99999 ( 99999 )
    -0.5 ( 0.71 )
    99999 ( 99999 )
    0.8 ( 1.79 )
    0.0 ( 1.73 )
    -2.0 ( 99999 )
    3.0 ( 4.24 )
    99999 ( 99999 )
    99999 ( 99999 )
    0.0 ( 0.00 )
        Cycle 19 Day 1, n=0,2,0,5,9,1,2,0,1,2
    99999 ( 99999 )
    -0.5 ( 0.71 )
    99999 ( 99999 )
    0.8 ( 1.79 )
    -0.6 ( 2.65 )
    0.0 ( 99999 )
    3.5 ( 4.95 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.5 ( 0.71 )
        Cycle 20 Day 1, n=0,2,0,5,9,1,2,0,1,2
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    0.0 ( 1.41 )
    0.7 ( 2.12 )
    0.0 ( 99999 )
    3.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.5 ( 0.71 )
        Cycle 21 Day 1, n=0,2,0,5,9,1,2,0,1,2
    99999 ( 99999 )
    -0.5 ( 0.71 )
    99999 ( 99999 )
    0.0 ( 1.41 )
    0.1 ( 2.09 )
    99999 ( 99999 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.5 ( 0.71 )
        Cycle 22 Day 1, n=0,2,0,5,9,1,2,0,1,3
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    0.4 ( 1.52 )
    0.1 ( 1.45 )
    0.0 ( 99999 )
    3.5 ( 3.54 )
    99999 ( 99999 )
    -1.0 ( 99999 )
    -0.3 ( 0.58 )
        Cycle 23 Day 1, n=0,2,0,5,8,1,2,0,1,2
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    0.0 ( 1.41 )
    0.1 ( 1.81 )
    -1.0 ( 99999 )
    1.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -2.3 ( 4.04 )
        Cycle 24 Day 1, n=0,2,0,5,8,1,2,0,1,2
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    -0.4 ( 0.89 )
    0.6 ( 0.74 )
    1.0 ( 99999 )
    1.5 ( 4.95 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 25 Day 1, n=0,2,0,5,7,1,2,0,1,2
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    0.8 ( 1.79 )
    -0.9 ( 2.27 )
    -2.0 ( 99999 )
    2.5 ( 4.95 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 26 Day 1, n=0,2,0,5,8,1,2,0,1,3
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    0.8 ( 1.79 )
    -0.4 ( 2.77 )
    -1.0 ( 99999 )
    2.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.3 ( 0.58 )
        Cycle 27 Day 1, n=0,2,0,5,7,1,2,0,1,2
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    0.8 ( 1.79 )
    -0.1 ( 2.67 )
    -1.0 ( 99999 )
    3.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -1.0 ( 1.41 )
        Cycle 28 Day 1, n=0,2,0,4,7,1,2,0,1,3
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    1.0 ( 2.00 )
    0.7 ( 0.76 )
    -2.0 ( 99999 )
    3.0 ( 2.83 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 29 Day 1, n=0,2,0,4,8,1,2,0,1,3
    99999 ( 99999 )
    -1.5 ( 2.12 )
    99999 ( 99999 )
    0.5 ( 1.73 )
    0.1 ( 1.81 )
    0.0 ( 99999 )
    3.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 30 Day 1, n=0,2,0,4,5,1,2,0,1,3
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    0.8 ( 1.50 )
    0.4 ( 0.55 )
    0.0 ( 99999 )
    3.0 ( 2.83 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -1.0 ( 1.00 )
        Cycle 31 Day 1, n=0,2,0,3,6,1,2,0,0,3
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    1.0 ( 2.65 )
    0.7 ( 0.82 )
    0.0 ( 99999 )
    3.0 ( 4.24 )
    99999 ( 99999 )
    99999 ( 99999 )
    0.0 ( 0.00 )
        Cycle 32 Day 1, n=0,2,0,3,5,0,2,0,1, 2
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    1.3 ( 2.31 )
    0.4 ( 0.55 )
    99999 ( 99999 )
    3.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 33 Day 1, n=0,2,0,3,4,0,2,0,1, 2
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    1.3 ( 2.31 )
    0.5 ( 0.58 )
    99999 ( 99999 )
    3.5 ( 3.54 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 34 Day 1, n=0,2,0,2,4,0,2,0,1, 2
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    0.0 ( 0.00 )
    0.3 ( 0.50 )
    99999 ( 99999 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
        Cycle 35 Day 1, n=0,2,0,1,4,0,2,0,1, 1
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.3 ( 0.50 )
    99999 ( 99999 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 99999 )
        Cycle 36 Day 1, n=0,2,0,1,3,0,2,0,1, 1
    99999 ( 99999 )
    -0.5 ( 0.71 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 99999 )
        Cycle 37 Day 1, n=0,2,0,1,2,0,2,0,0,0
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    -1.0 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    3.5 ( 4.95 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 38 Day 1, n=0,2,0,1,2,0,2,0,1,0
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    3.0 ( 2.83 )
    99999 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
        Cycle 39 Day 1, n=0,1,0,1,2,0,2,0,0,0
    99999 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    0.0 ( 99999 )
    -0.5 ( 0.71 )
    99999 ( 99999 )
    3.5 ( 4.95 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 40 Day 1, n=0,1,0,1,1,0,2,0,0,0
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    -1.0 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 41 Day 1, n=0,2,0,1,1,0,2,0,0,0
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    1.5 ( 6.36 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 42 Day 1, n=0,2,0,1,1,0,2,0,0,0
    99999 ( 99999 )
    -0.5 ( 0.71 )
    99999 ( 99999 )
    0.0 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 43 Day 1, n=0,2,0,1,0,0,2,0,0,0
    99999 ( 99999 )
    0.0 ( 0.00 )
    99999 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    4.0 ( 4.24 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 44 Day 1, n=0,2,0,1,0,0,2,0,0,0
    99999 ( 99999 )
    1.0 ( 99999 )
    99999 ( 99999 )
    -1.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    3.0 ( 4.24 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 45 Day 1, n=0,1,0,1,0,0,1,0,0,0
    99999 ( 99999 )
    1.0 ( 99999 )
    99999 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    1.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 46 Day 1, n=0,1,0,1,0,0,0,0,0,0
    99999 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    -1.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 47 Day 1, n=0,1,0,1,0,0,0,0,0,0
    99999 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 48 Day 1, n=0,1,0,1,0,0,0,0,0,0
    99999 ( 99999 )
    -3.0 ( 99999 )
    99999 ( 99999 )
    0.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 49 Day 1, n=0,2,0,0,0,0,0,0,0,0
    99999 ( 99999 )
    0.5 ( 0.71 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 50 Day 1, n=0,1,0,0,0,0,0,0,0,0
    99999 ( 99999 )
    -3.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 51 Day 1, n=0,1,0,0,0,0,0,0,0,0
    99999 ( 99999 )
    -0.5 ( 0.71 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        Cycle 52 Day 1, n=0,1,0,0,0,0,0,0,0,0
    99999 ( 99999 )
    1.0 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        End of treatment, n=1,0,3,1,4,0,0,1,1
    -8.0 ( 99999 )
    99999 ( 99999 )
    0.7 ( 1.15 )
    -2.0 ( 99999 )
    -2.3 ( 5.19 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    -15.0 ( 99999 )
    0.0 ( 99999 )
    No statistical analyses for this end point

    Secondary: Time to Tumor Response (TTR) and Intracranial TTR (Phase 2 and DDI sub-study)

    Close Top of page
    End point title
    Time to Tumor Response (TTR) and Intracranial TTR (Phase 2 and DDI sub-study) [28]
    End point description
    TTR: time from first dose of study treatment to first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, onset of PR was taken as onset of response. TTR was calculated for subgroup of participants with confirmed objective tumor response. Intracranial TTR was calculated for participants with confirmed intracranial objective response. CR: disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to <10 mm. PR: 30% or more decrease in SLD of target lesions, taking as reference baseline SLD. TTR analysis set: ITT participants who had confirmed objective response; intracranial TTR analysis set:all ITT participants who had CNS metastases,achieved confirmed intracranial objective response."Number Analyzed": participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment until CR or PR (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) DDI Substudy
    Number of subjects analysed
    27
    21
    34
    26
    17
    18
    13
    Units: Months
    median (full range (min-max))
        TTR, n=27,21,34,26,17,18,13
    1.4 (1.2 to 5.4)
    1.4 (1.2 to 18.0)
    1.4 (1.1 to 16.6)
    2.6 (1.2 to 16.4)
    1.4 (1.2 to 9.3)
    1.4 (1.3 to 29.7)
    1.4 (1.2 to 11.0)
        Intracranial TTR, n=6,10,22,24,16,14,4
    2.1 (1.2 to 2.8)
    1.4 (1.2 to 1.5)
    1.4 (1.1 to 5.7)
    1.7 (1.2 to 17.5)
    1.4 (1.2 to 10.6)
    1.4 (1.2 to 28.9)
    2.0 (1.1 to 4.2)
    No statistical analyses for this end point

    Secondary: Duration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy)

    Close Top of page
    End point title
    Duration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy) [29]
    End point description
    DOR: time from first documentation of objective tumor response (CR/PR) to first documentation of PD or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial(IC) DOR: calculated for participants with confirmed IC OR. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to <10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in SLD of target lesion relative to baseline or smallest SLD (nadir) recorded since first dose, demonstrate absolute increase of at least 5mm (>=5mm) relative to baseline or smallest SLD.99999: Upper limit could not be calculated due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) DDI Substudy
    Number of subjects analysed
    27
    21
    34
    26
    17
    18
    13
    Units: Months
    median (confidence interval 95%)
        DOR, n=27,21,34,26,17,18,13
    17.16 (12.45 to 35.09)
    16.56 (4.20 to 99999)
    11.10 (5.55 to 99999)
    15.08 (5.55 to 26.28)
    7.03 (4.17 to 11.01)
    19.61 (11.10 to 99999)
    5.19 (4.17 to 99999)
        Intra-cranial DOR, n=6,10,22,24,16,14,4
    99999 (8.28 to 99999)
    99999 (20.99 to 99999)
    37.12 (8.38 to 99999)
    14.52 (11.07 to 99999)
    10.32 (6.90 to 14.98)
    17.62 (4.99 to 99999)
    99999 (2.76 to 99999)
    No statistical analyses for this end point

    Secondary: Percentage of Participants Achieving Disease Control and Intracranial Disease Control at Week 12 and 24 (Phase 2 and DDI Substudy)

    Close Top of page
    End point title
    Percentage of Participants Achieving Disease Control and Intracranial Disease Control at Week 12 and 24 (Phase 2 and DDI Substudy) [30]
    End point description
    Tumor response was evaluated according to RECIST version 1.1, and disease control:confirmed CR, PR, or stable disease (SD). CR: disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to <10 mm. PR: 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. SD= when neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD is observed, taking as reference smallest sum diameters while on study. Intracranial assessment was only performed for participants CNS metastases. ITT analysis set:all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with CNS metastases in ITT analysis set was used for intracranial response assessment. 'Number Analyzed': participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Weeks 12 and 24
    Notes
    [30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) DDI Substudy
    Number of subjects analysed
    30
    27
    60
    65
    46
    47
    32
    Units: Percentage of participants
    number (confidence interval 95%)
        DCR at Week 12, n=30,27,60,65,47,47,32
    93.3 (77.9 to 99.2)
    85.2 (66.3 to 95.8)
    68.3 (55.0 to 79.7)
    64.6 (51.8 to 76.1)
    50.0 (34.9 to 65.1)
    66.0 (50.7 to 79.1)
    56.3 (37.7 to 73.6)
        DCR at Week 24, n=30,27,60,65,47,47,32
    83.3 (65.3 to 94.4)
    63.0 (42.4 to 80.6)
    51.7 (38.4 to 64.8)
    49.2 (36.6 to 61.9)
    32.6 (19.5 to 48.0)
    48.9 (34.1 to 63.9)
    34.4 (18.6 to 53.2)
        Intra-cranial DCR at Week 12,n=8,17,33,45,37,25,16
    87.5 (47.3 to 99.7)
    94.1 (71.3 to 99.9)
    75.8 (57.7 to 88.9)
    75.6 (60.5 to 87.1)
    67.6 (50.2 to 82.0)
    72.0 (50.6 to 87.9)
    56.3 (29.9 to 80.2)
        Intra-cranial DCR at Week 24,n=8,17,33,45,37,25,16
    75.0 (34.9 to 96.8)
    70.6 (44.0 to 89.7)
    60.6 (42.1 to 77.1)
    62.2 (46.5 to 76.2)
    48.6 (31.9 to 65.6)
    52.0 (31.3 to 72.2)
    43.8 (19.8 to 70.1)
    No statistical analyses for this end point

    Secondary: Time to Progression on the Last Prior Therapy (Phase 2)

    Close Top of page
    End point title
    Time to Progression on the Last Prior Therapy (Phase 2) [31]
    End point description
    TTP on last prior therapy was defined as time from first dose date of last prior treatment regimen to date of progression. Progressive disease: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must also demonstrate an absolute increase of at least 5 mm (>= 5 mm) relative to baseline or smallest SLD (nadir) recorded since first dose.ITT analysis set: all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922. As planned in SAP, this outcome measure was not analyzed for EXP-1 and EXP-6 groups. Number Analyzed: participants evaluable for specified rows. 99999: Upper limit could not be calculated due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment until progression (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2)
    Number of subjects analysed
    27
    60
    65
    46
    Units: Months
    median (confidence interval 95%)
        Prior systemic therapy before PF-06463922
    11.5 (7.2 to 19.6)
    12.8 (10.9 to 16.9)
    10.2 (7.6 to 15.9)
    3.7 (2.1 to 6.4)
        Prior ALK+/ROS1+ TKI treatment
    11.5 (7.2 to 19.6)
    13.8 (11.2 to 18.1)
    12.1 (7.9 to 16.4)
    3.7 (2.1 to 6.6)
        Prior systemic therapy other than ALK+/ROS1+ TKI
    19.6 (16.1 to 99999)
    8.5 (5.0 to 12.6)
    5.0 (3.1 to 10.0)
    5.6 (3.5 to 11.2)
    No statistical analyses for this end point

    Secondary: Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy)

    Close Top of page
    End point title
    Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy) [32]
    End point description
    TTP: time from first dose of study treatment to first documentation of objective PD. Intracranial TTP: time from first dose of study treatment to date of first documentation of objective progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases.PD: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must also demonstrate absolute increase of at least 5 mm (>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since first dose. ITT analysis set: all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; ITT participants with CNS metastases were analyzed for intracranial TTP.99999: Upper limit could not be calculated due to insufficient number of participants with events. Median and Upper limit could not be calculated due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment until progression (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) DDI Substudy
    Number of subjects analysed
    30
    27
    60
    65
    46
    47
    32
    Units: Months
    median (confidence interval 95%)
        TTP
    17.7 (12.5 to 40.5)
    20.6 (5.5 to 99999)
    8.2 (5.5 to 12.5)
    8.4 (5.6 to 13.7)
    5.6 (4.0 to 8.3)
    12.5 (8.2 to 26.2)
    5.7 (4.1 to 8.3)
        Intracranial TTP
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    99999 (15.0 to 99999)
    22.1 (15.7 to 99999)
    16.4 (12.7 to 99999)
    99999 (34.5 to 99999)
    99999 (6.9 to 99999)
    No statistical analyses for this end point

    Secondary: Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)

    Close Top of page
    End point title
    Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)
    End point description
    Probability of first event being CNS progression, non-CNS progression, or death was evaluated with competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to analysis set. Time to first event being Competing Event (either CNS progression or non CNS progression or Death)=time from first dose until date of that specific event. Participants not known to have any of Competing Events were censored on date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as competing cause of failure for analysis of other type of events. PD:20% or more increase in SLD of target lesion relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must demonstrate absolute increase of atleast 5mm(>=5 mm) relative to baseline or smallest SLD (nadir) recorded since first dose.ITT analysis set: all enrolled participants with documented ALK or ROS1 rearrangement & received at least 1 dose of PF-06463922.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment until progression (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    End point values
    Phase 2 ITT Population
    Number of subjects analysed
    274
    Units: Probability of events
    number (not applicable)
        CNS progression
    0.179
        Non CNS progression
    0.325
        Death
    0.055
    No statistical analyses for this end point

    Secondary: Progression-Free Survival (PFS) (Phase 2 and DDI Substudy)

    Close Top of page
    End point title
    Progression-Free Survival (PFS) (Phase 2 and DDI Substudy) [33]
    End point description
    PFS was defined as time from first dose of study treatment to first documentation of objective disease progression or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition to relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (>= 5 mm) relative to baseline or smallest SLD (nadir) recorded since first dose. Results presented here were based on independent central review. PFS analysis set included all participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922. 99999: Upper limit could not be calculated due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to first documentation of objective disease progression or death due to any cause, whichever came first(maximum of 89.65 month of treatment exposure-Phase 2, maximum of 68.69 month of treatment exposure-DDI participant)
    Notes
    [33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) DDI Substudy
    Number of subjects analysed
    30
    27
    60
    65
    46
    47
    32
    Units: Months
        median (confidence interval 95%)
    16.6 (11.8 to 28.3)
    20.6 (5.5 to 99999)
    6.9 (5.5 to 11.0)
    7.3 (4.2 to 11.1)
    5.5 (3.9 to 8.2)
    9.9 (5.5 to 21.0)
    5.7 (4.0 to 7.1)
    No statistical analyses for this end point

    Secondary: Overall Survival (Phase 2 and DDI Substudy)

    Close Top of page
    End point title
    Overall Survival (Phase 2 and DDI Substudy) [34]
    End point description
    OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method. ITT analysis set: all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922. 99999: Median and upper limit could not be calculated due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment until date of death (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) DDI Substudy
    Number of subjects analysed
    30
    27
    60
    65
    46
    47
    32
    Units: Months
        median (confidence interval 95%)
    99999 (99999 to 99999)
    52.5 (24.4 to 99999)
    99999 (38.5 to 99999)
    18.7 (15.1 to 34.1)
    20.4 (10.5 to 31.6)
    49.7 (21.0 to 99999)
    19.8 (11.1 to 99999)
    No statistical analyses for this end point

    Secondary: Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)

    Close Top of page
    End point title
    Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)
    End point description
    Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, "Overall Number Analyzed" signifies participants analyzed for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    End point values
    Phase 2 and Japan LIC PK Analysis Set
    Number of subjects analysed
    22
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Day -7, n=19
    695.2 ( 40 )
        Cycle 1 Day 15, n=22
    576.5 ( 42 )
    No statistical analyses for this end point

    Secondary: Time for Cmax (Tmax) of PF-06463922 (Phase 2)

    Close Top of page
    End point title
    Time for Cmax (Tmax) of PF-06463922 (Phase 2)
    End point description
    Tmax of PF-06463922 was observed directly from data as time of first occurrence. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, "Number Analyzed" signifies participants analyzed for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    End point values
    Phase 2 and Japan LIC PK Analysis Set
    Number of subjects analysed
    22
    Units: Hours
    median (full range (min-max))
        Day -7, n=19
    1.15 (0.50 to 4.02)
        Cycle 1 Day 15, n=22
    1.96 (0.50 to 22.7)
    No statistical analyses for this end point

    Secondary: Area under the Plasma Concentration-Time Profile from Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)

    Close Top of page
    End point title
    Area under the Plasma Concentration-Time Profile from Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)
    End point description
    AUCinf was calculated as AUClast + (Clast*/kel), where AUClast was area under plasma concentration-time profile from time 0 to time of last quantifiable concentration, Clast* was predicted plasma concentration at last quantifiable time point estimated from log-linear regression analysis, and kel was rate constant for terminal phase.PK parameter analysis set for PF-06463922: all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of PK parameters of interest for PF-06463922. Here, ‘Overall Number of Participants Analyzed' signifies participants analyzed for this outcome measure.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
    End point values
    Phase 2 and Japan LIC PK Analysis Set
    Number of subjects analysed
    16
    Units: ng*hour/mL
        geometric mean (geometric coefficient of variation)
    9088 ( 35 )
    No statistical analyses for this end point

    Secondary: Area under the Plasma Concentration-Time profile from Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)

    Close Top of page
    End point title
    Area under the Plasma Concentration-Time profile from Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)
    End point description
    Tau refers to the dosing interval, and it equals to 24 hours for QD dosing which was adopted in Phase 2. AUCtau was determined using linear/log trapezoidal method. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, 'Number Analyzed' signifies participants evaluable for specified row.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    End point values
    Phase 2 and Japan LIC PK Analysis Set
    Number of subjects analysed
    22
    Units: ng*hour/mL
    geometric mean (geometric coefficient of variation)
        Day -7, n=19
    5308 ( 36 )
        Cycle 1 Day 15, n=22
    5650 ( 39 )
    No statistical analyses for this end point

    Secondary: Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)

    Close Top of page
    End point title
    Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)
    End point description
    Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
    End point values
    Phase 2 and Japan LIC PK Analysis Set
    Number of subjects analysed
    16
    Units: Liters
        geometric mean (geometric coefficient of variation)
    351.5 ( 37 )
    No statistical analyses for this end point

    Secondary: Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)

    Close Top of page
    End point title
    Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)
    End point description
    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, 'Number Analyzed' signifies participants evaluable for specified row.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    End point values
    Phase 2 and Japan LIC PK Analysis Set
    Number of subjects analysed
    22
    Units: Liter/hour
    geometric mean (geometric coefficient of variation)
        Day -7, n=16
    11.01 ( 35 )
        Cycle 1 Day 15, n=22
    17.70 ( 39 )
    No statistical analyses for this end point

    Secondary: Terminal Half-Life of PF-06463922 (Phase 2)

    Close Top of page
    End point title
    Terminal Half-Life of PF-06463922 (Phase 2)
    End point description
    Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
    End point values
    Phase 2 and Japan LIC PK Analysis Set
    Number of subjects analysed
    16
    Units: Hours
        arithmetic mean (standard deviation)
    23.58 ( 9.3743 )
    No statistical analyses for this end point

    Secondary: Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)

    Close Top of page
    End point title
    Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)
    End point description
    Rac was calculated as Day 15 AUCtau/Day -7 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2). PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    End point values
    Phase 2 and Japan LIC PK Analysis Set
    Number of subjects analysed
    20
    Units: Ratio
        arithmetic mean (standard deviation)
    1.082 ( 0.42701 )
    No statistical analyses for this end point

    Secondary: Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)

    Close Top of page
    End point title
    Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)
    End point description
    Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
    End point values
    Phase 2 and Japan LIC PK Analysis Set
    Number of subjects analysed
    14
    Units: Ratio
        arithmetic mean (standard deviation)
    0.6577 ( 0.28627 )
    No statistical analyses for this end point

    Secondary: Number of Participants with ALK Mutation Based on Tumor Tissue Analysis (Phase 2)

    Close Top of page
    End point title
    Number of Participants with ALK Mutation Based on Tumor Tissue Analysis (Phase 2) [35]
    End point description
    Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented. Tumor Tissue analysis set included all participants of the ITT analysis set who had at least 1 molecular tumor biomarker assayed from either the screening archival or screening de novo tumor biopsy sample (or both). Tumor Tissue analysis set included all participants of the ITT analysis set who had at least 1 molecular tumor biomarker assayed from either the screening archival or screening de novo tumor biopsy sample (or both).
    End point type
    Secondary
    End point timeframe
    Screening (up to 28 days)
    Notes
    [35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2)
    Number of subjects analysed
    29
    26
    58
    63
    44
    Units: Participants
    0
    7
    8
    12
    13
    No statistical analyses for this end point

    Secondary: Number of Participants with ALK Mutation Based on Plasma CNA Analysis (Phase 2)

    Close Top of page
    End point title
    Number of Participants with ALK Mutation Based on Plasma CNA Analysis (Phase 2) [36]
    End point description
    Plasma CNA samples were analyzed for ALK kinase domain mutations by Next Generation Sequencing (NGS). Number of participants with one or more ALK mutations is presented. CNA peripheral blood analysis set included all participants of the ITT analysis set who had at least 1 molecular biomarker assayed. CNA peripheral blood analysis set included all participants of the ITT analysis set who had at least 1 molecular biomarker assayed. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    Screening (up to 28 days)
    Notes
    [36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2)
    Number of subjects analysed
    30
    26
    59
    61
    46
    Units: Participants
    0
    6
    8
    17
    14
    No statistical analyses for this end point

    Secondary: Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI sub-study)

    Close Top of page
    End point title
    Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI sub-study) [37]
    End point description
    EORTC QLQ-C30 (v3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global QoL, disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement: increase of at least 10 points, worsening: decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement: decrease of at least 10 points, worsening: increase of at least 10 points. All scales which had not improved nor worsened were considered stable.PRO evaluable analysis set: all enrolled participants who received at least 1 dose of PF-06463922 and completed baseline, at least 1 post-baseline PRO assessment.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) DDI Substudy
    Number of subjects analysed
    30
    26
    55
    60
    43
    41
    32
    Units: Participants
        Improved in global QoL, n=30,26,55,60,43,41,32
    17
    11
    18
    25
    17
    19
    12
        Stable in global QoL,n=30,26,55,60,43,41,32
    10
    12
    24
    22
    16
    15
    18
        Worsened in global QoL,n=30,26,55,60,43,41,32
    3
    3
    13
    13
    10
    6
    2
        Improved physical function,n=30,26,55,60,43,41,32
    11
    8
    13
    24
    8
    11
    5
        Stable physical function,n=30,26,55,60,43,41,32
    13
    17
    38
    24
    25
    23
    23
        Worsened physical function,n=30,26,55,60,43,41,32
    6
    1
    4
    12
    10
    6
    4
        Improved in role function,n=30,26,55,60,43,39,32
    12
    7
    15
    25
    18
    17
    10
        Stable role function,n=30,26,55,60,43,39,32
    9
    16
    33
    18
    13
    17
    15
        Worsened role function,n=30,26,55,60,43,39,32
    9
    3
    7
    17
    12
    5
    7
        Improved emotional function,n=30,26,55,60,43,41,32
    13
    12
    13
    20
    17
    16
    10
        Stable emotional function,n=30,26,55,60,43,41,32
    13
    14
    32
    34
    20
    22
    20
        Worsened emotional function,n=30,26,55,60,43,41,32
    4
    0
    10
    6
    6
    2
    2
        Improved cognitive function,n=30,26,55,60,43,41,32
    9
    4
    5
    12
    12
    12
    9
        Stable cognitive function,n=30,26,55,60,43,41,32
    12
    14
    36
    34
    19
    20
    11
        Worsened cognitive function,n=30,26,55,60,43,41,32
    9
    8
    14
    14
    12
    8
    12
        Improved social function,n=30,26,55,60,43,41,32
    14
    7
    16
    20
    11
    13
    13
        Stable in social function,n=30,26,55,60,43,41,32
    11
    16
    33
    29
    21
    18
    13
        Worsened social function,n=30,26,55,60,43,41,32
    5
    3
    6
    11
    11
    9
    6
        Improved fatigue,n=30,26,55,60,43,41,32
    18
    14
    22
    28
    26
    16
    17
        Stable in fatigue,n=30,26,55,60,43,41,32
    8
    11
    25
    23
    9
    20
    9
        Worsened in fatigue,n=30,26,55,60,43,41,32
    4
    1
    8
    9
    8
    4
    6
        Improved nausea & vomiting,n=30,26,55,60,43,41,32
    8
    5
    10
    16
    13
    10
    6
        Stable nausea & vomiting,n=30,26,55,60,43,41,32
    22
    21
    44
    39
    28
    28
    24
        Worsened nausea & vomiting,n=30,26,55,60,43,41,32
    0
    0
    1
    5
    2
    2
    2
        Improved in pain,n=30,26,55,60,43,41,32
    13
    10
    20
    23
    19
    21
    14
        Stable in pain,n=30,26,55,60,43,41,32
    10
    14
    25
    28
    19
    12
    13
        Worsened in pain,n=30,26,55,60,43,41,32
    7
    2
    10
    9
    5
    7
    5
        Improved in dyspnea,n=30,26,55,60,43,41,32
    16
    10
    10
    23
    14
    14
    9
        Stable in dyspnea,n=30,26,55,60,43,41,32
    10
    14
    33
    22
    18
    17
    15
        Worsened in dyspnea,n=30,26,55,60,43,41,32
    4
    2
    12
    15
    11
    9
    8
        Improved in insomnia,n=30,26,55,60,43,41,32
    20
    8
    18
    30
    21
    19
    12
        Stable in insomnia,n=30,26,55,60,43,41,32
    9
    13
    28
    22
    16
    18
    15
        Worsened in insomnia,n=30,26,55,60,43,41,32
    1
    5
    9
    8
    6
    3
    5
        Improved in appetite loss,n=30,26,55,60,43,41,32
    14
    4
    18
    29
    22
    20
    10
        Stable in appetite loss,n=30,26,55,60,43,41,32
    16
    22
    36
    26
    21
    20
    20
        Worsened in appetite loss,n=30,26,55,60,43,41,32
    0
    0
    1
    5
    0
    0
    2
        Improved in constipation,n=30,26,55,60,43,41,32
    10
    5
    9
    16
    11
    13
    10
        Stable in constipation,n=30,26,55,60,43,41,32
    14
    19
    33
    33
    29
    22
    12
        Worsened in constipation,n=30,26,55,60,43,41,32
    6
    2
    13
    11
    3
    5
    10
        Improved in diarrhea,n=30,26,55,60,43,41,32
    5
    3
    10
    10
    10
    8
    6
        Stable in diarrhea,n=30,26,55,60,43,41,32
    18
    21
    40
    39
    27
    28
    21
        Worsened in diarrhea,n=30,26,55,60,43,41,32
    7
    2
    5
    11
    6
    4
    5
        Improved finance difficulty,n=30,26,55,60,43,41,32
    10
    6
    11
    13
    10
    10
    9
        Stable financial difficulty,n=30,26,55,60,43,41,32
    17
    19
    34
    38
    22
    26
    16
        Worsen financial difficulty,n=30,26,55,60,43,41,32
    3
    1
    10
    9
    11
    4
    7
    No statistical analyses for this end point

    Secondary: Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI sub-study)

    Close Top of page
    End point title
    Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI sub-study) [38]
    End point description
    EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. Scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement: decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable. PRO evaluable analysis set: all enrolled participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) DDI Substudy
    Number of subjects analysed
    30
    26
    55
    60
    43
    41
    32
    Units: Participants
        Improved in dyspnea
    11
    5
    9
    21
    12
    12
    6
        Stable in dyspnea
    16
    18
    36
    25
    21
    23
    18
        Worsened in dyspnea
    3
    3
    10
    14
    9
    6
    8
        Improved in coughing
    18
    9
    22
    26
    18
    17
    16
        Stable in coughing
    9
    13
    26
    28
    15
    18
    15
        Worsened in coughing
    3
    4
    7
    6
    9
    6
    1
        Improved in hemoptysis
    4
    0
    7
    5
    5
    4
    1
        Stable in hemoptysis
    24
    25
    47
    52
    34
    36
    31
        Worsened in hemoptysis
    2
    1
    1
    3
    3
    1
    0
        Improved in sore mouth
    0
    2
    4
    9
    2
    5
    4
        Stable in sore mouth
    25
    20
    44
    41
    33
    28
    26
        Worsened in sore mouth
    5
    4
    7
    10
    7
    8
    2
        Improved in dysphagia
    3
    1
    3
    7
    4
    5
    3
        Stable in dysphagia
    23
    24
    46
    48
    33
    30
    27
        Worsened in dysphagia
    4
    1
    6
    5
    5
    6
    2
        Improved in peripheral neuropathy
    4
    5
    9
    5
    6
    9
    9
        Stable in peripheral neuropathy
    10
    13
    27
    33
    22
    18
    16
        Worsened in peripheral neuropathy
    16
    8
    19
    22
    14
    14
    7
        Improved in alopecia
    2
    1
    2
    10
    10
    9
    4
        Stable in alopecia
    18
    22
    41
    40
    24
    27
    21
        Worsened in alopecia
    10
    3
    12
    10
    8
    5
    7
        Improved in chest pain
    11
    7
    13
    18
    14
    14
    13
        Stable in chest pain
    17
    17
    35
    33
    25
    24
    17
        Worsened in chest pain
    2
    2
    6
    9
    3
    3
    2
        Improved in arm or shoulder pain
    10
    5
    14
    14
    12
    12
    9
        Stable in arm or shoulder pain
    15
    19
    30
    36
    21
    22
    19
        Worsened in arm or shoulder pain
    5
    2
    11
    10
    9
    7
    4
        Improved in pain in other parts
    9
    6
    17
    20
    15
    17
    9
        Stable in pain in other parts
    14
    15
    23
    24
    9
    18
    10
        Worsened in pain in other parts
    7
    5
    15
    16
    17
    6
    12
    No statistical analyses for this end point

    Secondary: Number of Participants with Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI sub-study)

    Close Top of page
    End point title
    Number of Participants with Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI sub-study) [39]
    End point description
    AE: any untoward medical occurrence in clinical investigation participant administered product or medical device, regardless of causal relationship to study treatment. Treatment-emergent AEs (TEAE): AE which occurred for first time during effective duration of treatment or AE that increased in severity during treatment. Serious AE (SAE): any untoward medical occurrence at any dose that resulted in death; was life-threatening, required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of ability to conduction normal life function). Severity graded as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.Grade (G)1: mild, G2:moderate, G3:severe, G4:Life threatening consequences; urgent intervention indicated, G5:death related to AE. Safety analysis set: all enrolled participants who received atleast 1 dose of PF-06463922.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) DDI Substudy Phase 2
    Number of subjects analysed
    3
    3
    3
    12
    17
    3
    3
    3
    3
    4
    32
    275
    Units: Participants
        AEs (all causality)
    3
    3
    3
    12
    17
    3
    3
    3
    3
    4
    32
    274
        AEs (treatment-related)
    3
    3
    3
    11
    16
    3
    3
    1
    3
    4
    31
    262
        SAEs (all causality)
    3
    2
    1
    6
    10
    3
    2
    2
    2
    2
    13
    135
        SAEs (treatment-related)
    1
    1
    0
    1
    1
    3
    0
    0
    0
    1
    1
    27
        Grade 3 or 4 (all causality)
    3
    3
    0
    6
    12
    3
    2
    2
    1
    4
    24
    209
        Grade 3 or 4 (treatment-related)
    2
    2
    0
    3
    6
    2
    0
    0
    1
    3
    16
    137
        Grade 5 (all causality)
    1
    1
    0
    1
    4
    2
    0
    0
    1
    0
    5
    43
        Grade 5 (treatment-related)
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Participants with Laboratory Abnormalities (Phase 1, Phase 2 and DDI sub-study) – Hematology

    Close Top of page
    End point title
    Number of Participants with Laboratory Abnormalities (Phase 1, Phase 2 and DDI sub-study) – Hematology [40]
    End point description
    Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils. Hematology parameters with any abnormalities were reported in this outcome measure. Safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922. Here, 'Number Analyzed' signifies participants evaluable for specified rows. All participants in Phase 2 received 100 mg of PF-06463922, hence combined data is presented for Phase 2.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) DDI Substudy Phase 2
    Number of subjects analysed
    3
    3
    3
    12
    17
    3
    3
    3
    3
    4
    32
    275
    Units: Participants
        Anemia, n=3,3,3,12,17,3,3,3,3,4,273,32
    3
    3
    3
    10
    16
    3
    3
    3
    3
    4
    25
    218
        Hb increased, n=3,3,3,12,17,3,3,3,3,4,273,32
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    7
        LC decreased, n=3,3,3,12,17,3,3,3,3,4,272,32
    2
    2
    2
    7
    4
    3
    3
    0
    0
    2
    15
    134
        LC increased, n=3,3,3,12,17,3,3,3,3,4,272,32
    0
    0
    0
    0
    3
    1
    0
    0
    0
    0
    2
    15
        NC decreased, n=3,3,3,12,17,3,3,3,3,4,272,32
    1
    0
    0
    4
    2
    0
    1
    0
    0
    1
    3
    37
        PC decreased, n=3,3,3,12,17,3,3,3,3,4,273,32
    2
    2
    0
    4
    5
    1
    0
    0
    0
    1
    8
    74
        WBC decreased, n=3,3,3,12,17,3,3,3,3,4,273,32
    2
    1
    0
    4
    2
    2
    2
    0
    0
    1
    4
    54
    No statistical analyses for this end point

    Secondary: Number of Participants with Laboratory Abnormalities (Phase 1, Phase 2 and DDI sub-study) – Chemistry

    Close Top of page
    End point title
    Number of Participants with Laboratory Abnormalities (Phase 1, Phase 2 and DDI sub-study) – Chemistry [41]
    End point description
    Chemistry evaluation included alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, creatine phosphokinase (CPK), creatinine, gamma-glutamyl transferase (GGT), calcium, sodium, potassium, magnesium, albumin, glucose (non-fasted), albumin, phosphorus or phosphate, serum amylase and lipase. The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable for specified rows. All participants in Phase 2 received 100 mg of PF-06463922, hence combined data is presented for Phase 2.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) DDI Substudy Phase 2
    Number of subjects analysed
    3
    3
    3
    12
    17
    3
    3
    3
    3
    4
    32
    273
    Units: Participants
        ALT increased, n=3,3,3,12,17,3,3,3,3,4,272,32
    2
    1
    1
    6
    9
    2
    2
    0
    0
    3
    10
    109
        ALP increased, n=3,3,3,12,17,3,3,3,3,4,272,32
    1
    1
    3
    6
    10
    3
    1
    0
    2
    3
    9
    118
        AST increased, n=3,3,3,12,17,3,3,3,3,4,272,32
    2
    2
    2
    5
    8
    2
    2
    0
    1
    3
    11
    139
        Bilirubin increased,n=3,3,3,12,17,3,3,3,3,4,272,32
    1
    0
    0
    1
    0
    0
    0
    0
    0
    1
    1
    8
        CPK increased, n=0,0,0,0,3,1,0,0,1,0,18,2
    99999
    99999
    99999
    99999
    1
    1
    99999
    99999
    1
    99999
    1
    9
        Creat. increased, n=3,3,3,12,17,3,3,3,3,4,273,32
    3
    2
    3
    10
    13
    3
    3
    2
    2
    3
    20
    209
        GGT increased, n=1,0,0,0,4,1,1,0,1,2,13,1
    0
    99999
    99999
    99999
    1
    0
    1
    99999
    0
    2
    0
    8
        Hypercalcemia, n=3,3,3,12,17,3,3,3,3,4,273,32
    0
    0
    0
    0
    3
    1
    0
    0
    0
    1
    5
    33
        Hyperglycemia, n=3,3,3,12,17,3,3,3,3,4,273,32
    3
    3
    2
    7
    8
    2
    1
    1
    2
    1
    23
    185
        Hyperkalemia, n=3,3,3,12,17,3,3,3,3,4,273,32
    0
    1
    2
    3
    6
    1
    1
    1
    1
    2
    5
    71
        Hypermagnesemia, n=3,3,3,12,17,3,3,3,3,4,272,32
    2
    0
    0
    2
    2
    0
    0
    0
    0
    0
    0
    14
        Hypernatremia, n=3,3,3,12,17,3,3,3,3,4,273,32
    0
    1
    0
    0
    4
    2
    0
    0
    0
    1
    3
    35
        Hypoalbuminemia, n=3,3,3,12,17,3,3,3,3,4,271,32
    2
    1
    3
    4
    7
    3
    1
    1
    3
    1
    18
    180
        Hypocalcemia, n=3,3,3,12,17,3,3,3,3,4,273,32
    1
    0
    1
    4
    5
    2
    1
    0
    0
    1
    6
    53
        Hypoglycemia, n=3,3,3,12,17,3,3,3,3,4,273,32
    0
    0
    1
    3
    4
    0
    1
    0
    1
    0
    6
    33
        Hypokalemia, n=3,3,3,12,17,3,3,3,3,4,273,32
    0
    0
    2
    4
    3
    3
    1
    1
    0
    2
    7
    57
        Hypomagnesemia, n=3,3,3,12,17,3,3,3,3,4,272,32
    0
    1
    2
    4
    2
    3
    0
    1
    1
    3
    15
    89
        Hyponatremia, n=3,3,3,12,17,3,3,3,3,4,273,32
    2
    1
    1
    2
    4
    1
    1
    0
    2
    2
    10
    78
        Hypophosphatemia, n=3,3,3,12,17,3,3,3,3,4,272,32
    1
    2
    0
    3
    3
    2
    1
    1
    2
    1
    9
    82
        Lipase increased, n=3,3,3,12,17,3,3,3,3,4,270,32
    3
    0
    0
    8
    6
    0
    1
    0
    2
    2
    7
    80
        S.amylase increased,n=3,3,1,11,16,3,3,3,2,4,265,32
    3
    0
    0
    2
    5
    0
    1
    0
    0
    2
    4
    83
    No statistical analyses for this end point

    Secondary: Number of Participants with Laboratory Abnormalities (Phase 1, Phase 2 and DDI sub-study) – Coagulation, Lipids and Urinalysis

    Close Top of page
    End point title
    Number of Participants with Laboratory Abnormalities (Phase 1, Phase 2 and DDI sub-study) – Coagulation, Lipids and Urinalysis [42]
    End point description
    Coagulation evaluation included activated partial thromboplastin time, international normalized ratio (INR), and prothrombin time. Lipid evaluation included Cholesterol and triglycerides. The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable for specified rows. All participants in Phase 2 received 100 mg of PF-06463922, hence combined data is presented for Phase 2.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) DDI Substudy Phase 2
    Number of subjects analysed
    3
    3
    3
    12
    17
    3
    3
    3
    3
    4
    32
    272
    Units: Participants
        APTT prolonged, n=3,3,3,11,14,3,3,3,3,3,82,21
    1
    0
    1
    3
    2
    0
    0
    0
    0
    0
    2
    14
        Cholesterol high, n=2,2,12,17,2,3,3,3,4,272,32
    2
    2
    2
    10
    16
    2
    3
    3
    2
    3
    31
    267
        Hypertriglyceridemia, n=1,2,12,17,2,3,3,3,4,272,32
    0
    2
    2
    11
    16
    2
    3
    2
    1
    3
    31
    261
        INR increased, n=3,3,3,11,14,3,3,3,3,3,113,24
    2
    1
    1
    2
    2
    1
    0
    0
    0
    0
    3
    21
        Prothrombin time, n=3,3,3,11,14,3,3,3,3,3,103,21
    2
    1
    1
    3
    3
    1
    0
    0
    1
    1
    6
    25
    No statistical analyses for this end point

    Secondary: Number of Participants with Vital Signs Data Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI sub-study)

    Close Top of page
    End point title
    Number of Participants with Vital Signs Data Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI sub-study) [43]
    End point description
    Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position. Body weight was also measured. The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified row. All participants in Phase 2 received 100 mg of PF-06463922, hence combined data is presented for Phase 2.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) DDI Substudy Phase 2
    Number of subjects analysed
    3
    3
    3
    12
    17
    3
    3
    3
    3
    4
    32
    273
    Units: Participants
        Increa.SBP>=40mmHg,n=3,3,3,12,17,3,3,3,3,4,270,32
    0
    0
    0
    0
    3
    2
    0
    0
    1
    0
    4
    45
        Increa.SBP>=60mmHg,n=3,3,3,12,17,3,3,3,3,4,270,32
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
        Decrea.SBP>=40mmHg,n=3,3,3,12,17,3,3,3,3,4,270,32
    0
    0
    0
    3
    2
    1
    0
    0
    0
    0
    1
    14
        Decrea.SBP>=60mmHg, n=3,3,3,12,17,3,3,3,3,4,270,32
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
        Increa.DBP>=20mmHg,n=3,3,3,12,17,3,3,3,3,4,270,32
    0
    2
    0
    0
    7
    3
    1
    0
    1
    0
    7
    86
        Increa.DBP>=40mmHg,n=3,3,3,12,17,3,3,3,3,4,270,32
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    8
        Decrea.DBP>=20mmHg,n=3,3,3,12,17,3,3,3,3,4,270,32
    2
    1
    0
    5
    3
    2
    2
    0
    1
    2
    8
    58
        Decrea.DBP>=40mmHg,n=3,3,3,12,17,3,3,3,3,4,270,32
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
        PR <50 bpm, n=3,3,3,12,17,3,3,3,3,4,273,32
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    2
    11
        PR>120 bpm,n=3,3,3,12,17,3,3,3,3,4,273,32
    0
    0
    1
    1
    2
    2
    0
    0
    0
    0
    3
    23
        Increase PR>=30 bpm,n=3,3,3,12,17,3,3,3,3,4,269,32
    0
    1
    0
    2
    7
    1
    0
    0
    0
    1
    8
    74
        Decrease PR>=30bpm,n=3,3,3,12,17,3,3,3,3,4,269,32
    0
    0
    1
    2
    0
    1
    0
    1
    1
    2
    4
    36
        Increase W:10-<20%,n=3,3,3,12,17,3,3,3,3,4,262,32
    1
    0
    0
    8
    6
    2
    2
    0
    0
    0
    9
    80
        Increased W:>=20%,n=3,3,3,12,17,3,3,3,3,4,262,32
    0
    2
    1
    1
    5
    1
    0
    0
    1
    1
    3
    58
        Decreased W>=10%,n=3,3,3,12,17,3,3,3,3,4,262,32
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    1
    14
    No statistical analyses for this end point

    Secondary: Number of Participants with Maximum Decrease from Baseline Greater than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI sub-study)

    Close Top of page
    End point title
    Number of Participants with Maximum Decrease from Baseline Greater than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI sub-study) [44]
    End point description
    Left Ventricular Ejection Fraction (LVEF) was determined by echocardiogram. Baseline was defined as the measurement prior to the first dose of study treatment. The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) DDI Substudy Phase 2
    Number of subjects analysed
    3
    3
    3
    12
    17
    3
    3
    3
    3
    4
    32
    275
    Units: Participants
    1
    0
    1
    3
    5
    2
    1
    0
    0
    2
    2
    41
    No statistical analyses for this end point

    Secondary: Number of Participants with Absolute Values and Change from Baseline in QTcF Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI sub-study)

    Close Top of page
    End point title
    Number of Participants with Absolute Values and Change from Baseline in QTcF Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI sub-study) [45]
    End point description
    Triplicate 12-lead electrocardiograms (ECGs) were performed approximately 2 minutes apart to determine mean QTc interval (QT interval corrected for heart rate). QT interval was corrected for heart rate using Fridericia’s formula to provide QTcF. Absolute values and changes from baseline were summarized according to pre-defined criteria. Baseline was defined as the last evaluation on or prior to the first dose of study treatment. The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    10 mg QD (Phase 1) 25 mg QD (Phase 1) 50 mg QD (Phase 1) 75 mg QD (Phase 1) 100 mg QD (Phase 1) 150 mg QD (Phase 1) 200 mg QD (Phase 1) 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) DDI Substudy Phase 2
    Number of subjects analysed
    3
    3
    3
    12
    17
    3
    3
    3
    3
    4
    32
    275
    Units: Participants
        QTcF: 450 to <480 msec
    1
    0
    0
    2
    1
    1
    0
    2
    0
    1
    7
    55
        QTcF: 480 to <500 msec
    1
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    7
        QTcF: >=500 msec
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    3
        QTcF Increase: 30 to <60 msec
    0
    0
    1
    3
    3
    0
    0
    1
    0
    1
    7
    75
        QTcF: >=60 msec
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    6
    No statistical analyses for this end point

    Secondary: Number of Participants with Suicidal Ideation and Suicidal Behavior (Phase 2)

    Close Top of page
    End point title
    Number of Participants with Suicidal Ideation and Suicidal Behavior (Phase 2) [46]
    End point description
    The Columbia Suicide Severity Rating Scale (C-SSRS) was used to analyze participants' suicidal ideation and behavior, and it is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation and deterrents), all of which are significantly predictive of completed suicide. Maximum score of 4 or 5 indicates maximum suicidal ideation and minimum score of “0” indicates no suicidal ideation. The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2)
    Number of subjects analysed
    26
    24
    52
    43
    30
    25
    Units: Participants
        Suicidal ideation
    1
    0
    2
    1
    1
    2
        Suicidal behavior
    0
    0
    0
    0
    0
    1
    No statistical analyses for this end point

    Secondary: Change from Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)

    Close Top of page
    End point title
    Change from Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2) [47]
    End point description
    Beck Depression Inventory (BDI)-II is a 21-item self-report scale, with each item rated by participants on a 4-point scale (ranging from 0-3, where 0 indicated lowest depression and 3 indicated severe depression). Scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike, pessimism, and poor concentration) as well as somatic signs (appetite, sleep, fatigue and libido). Scores were obtained by adding up the total points from the series of answers. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression. PRO evaluable analysis set: all enrolled participants who received study treatment, had baseline test assessment and at least 1 on-study test assessment. 'Number Analyzed' signifies participants evaluable for specified row.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
    Notes
    [47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2)
    Number of subjects analysed
    24
    24
    53
    41
    28
    26
    Units: Units on scale
    least squares mean (confidence interval 95%)
        Cycle 2 Day 1, n=24,24,53,41,28,26
    -2.59 (-4.82 to -0.37)
    -3.27 (-5.52 to -1.01)
    -2.26 (-3.77 to -0.76)
    -2.17 (-3.89 to -0.46)
    -1.52 (-3.60 to 0.56)
    -2.43 (-4.57 to -0.29)
        Cycle 3 Day 1, n=24,24,53,41,28,26
    -3.34 (-5.57 to -1.12)
    -3.18 (-5.43 to -0.93)
    -3.03 (-4.55 to -1.51)
    -3.10 (-4.85 to -1.35)
    -0.46 (-2.61 to 1.69)
    -1.24 (-3.37 to 0.90)
        Cycle 4 Day 1, n=24,24,53,41,28,26
    -3.84 (-6.07 to -1.62)
    -4.10 (-6.38 to -1.82)
    -2.59 (-4.14 to -1.05)
    -1.95 (-3.72 to -0.19)
    -1.19 (-3.38 to 1.01)
    -1.94 (-4.12 to 0.24)
        Cycle 5 Day 1, n=24,24,53,41,28,26
    -4.47 (-6.69 to -2.24)
    -3.96 (-6.27 to -1.66)
    -2.75 (-4.33 to -1.16)
    -3.03 (-4.82 to -1.25)
    -1.51 (-3.74 to 0.72)
    -1.25 (-3.46 to 0.95)
        Cycle 6 Day 1, n=24,24,53,41,28,26
    -3.51 (-5.73 to -1.28)
    -4.25 (-6.56 to -1.94)
    -3.31 (-4.90 to -1.72)
    -3.79 (-5.61 to -1.98)
    -0.42 (-2.64 to 1.81)
    -0.29 (-2.54 to 1.96)
        Cycle 8 Day 1, n=24,24,53,41,28,26
    -4.17 (-6.41 to -1.92)
    -4.86 (-7.23 to -2.50)
    -2.26 (-3.86 to -0.66)
    -4.06 (-5.90 to -2.22)
    -1.09 (-3.34 to 1.17)
    0.17 (-2.10 to 2.45)
        Cycle 10 Day 1, n=24,24,53,41,28,26
    -3.09 (-5.38 to -0.80)
    -4.92 (-7.28 to -2.55)
    -1.94 (-3.54 to -0.34)
    -4.27 (-6.14 to -2.39)
    -2.97 (-5.29 to -0.66)
    -0.19 (-2.60 to 2.22)
        Cycle 12 Day 1, n=24,24,53,41,28,26
    -3.95 (-6.30 to -1.61)
    -5.60 (-7.97 to -3.24)
    -0.72 (-2.40 to 0.95)
    -4.80 (-6.83 to -2.77)
    -1.94 (-4.29 to 0.42)
    -1.40 (-3.81 to 1.01)
        Cycle 14 Day 1, n=24,24,53,41,28,26
    -3.81 (-6.18 to -1.43)
    -5.80 (-8.35 to -3.25)
    -2.58 (-4.41 to -0.76)
    -4.29 (-6.41 to -2.17)
    -1.73 (-4.40 to 0.94)
    -0.08 (-2.59 to 2.42)
        Cycle 16 Day 1, n=24,24,53,41,28,26
    -1.75 (-4.40 to 0.89)
    -4.61 (-7.51 to -1.71)
    -2.15 (-4.35 to 0.06)
    -4.65 (-6.90 to -2.41)
    -2.22 (-5.50 to 1.07)
    0.03 (-2.65 to 2.71)
        Cycle 18 Day 1, n=24,24,53,41,28,26
    -4.49 (-7.49 to -1.49)
    -7.02 (-10.59 to -3.46)
    -1.96 (-4.22 to 0.31)
    -2.86 (-5.21 to -0.51)
    -1.11 (-8.25 to 6.03)
    1.88 (-1.66 to 5.41)
        Cycle 20 Day 1, n=24,24,53,41,0,26
    -5.01 (-8.55 to -1.46)
    -5.17 (-9.06 to -1.29)
    -1.82 (-4.70 to 1.06)
    -3.63 (-6.31 to -0.95)
    99999 (99999 to 99999)
    1.88 (-1.66 to 5.41)
        Cycle 22 Day 1, n=24,24,53,41,0,26
    -2.93 (-6.79 to 0.94)
    -4.63 (-9.00 to -0.26)
    -2.36 (-5.68 to 0.96)
    -5.50 (-8.87 to -2.12)
    99999 (99999 to 99999)
    -2.39 (-6.73 to 1.94)
        Cycle 24 Day 1, n=24,24,53,41,0,26
    -7.31 (-11.66 to -2.96)
    -5.63 (-10.00 to -1.26)
    -2.88 (-7.04 to 1.28)
    -3.89 (-8.10 to 0.32)
    99999 (99999 to 99999)
    2.27 (-2.06 to 6.61)
        Cycle 26 Day 1, n=24,24,53,41,0,0
    -5.50 (-10.67 to -0.33)
    99999 (99999 to 99999)
    -3.03 (-10.01 to 3.95)
    -4.30 (-11.31 to 2.70)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
        End of treatment, n=24,24,53,41,28,26
    -4.77 (-9.23 to -0.32)
    -0.73 (-5.61 to 4.15)
    -2.55 (-5.28 to 0.18)
    -3.22 (-5.49 to -0.95)
    0.74 (-2.70 to 4.17)
    -2.08 (-5.65 to 1.50)
    No statistical analyses for this end point

    Secondary: Change from Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)

    Close Top of page
    End point title
    Change from Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2) [48]
    End point description
    Detection Test is measure of psychomotor function, uses well validated simple reaction time paradigm with playing card stimuli. In this test, on-screen instructions ask: “Has the card turned over?”.Playing card is presented face down in center of screen. Card flips over so it is face up. As soon as card flips over participant must press “Yes”. Participant is encouraged to work as quickly as they can, be as accurate as possible. Speed and accuracy of each response are recorded, mean of log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline. PRO evaluable analysis set: all enrolled participants who received study treatment, had baseline test assessment, at least 1 on-study test assessment. 'Number Analyzed': participants evaluable for specified row.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
    Notes
    [48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2)
    Number of subjects analysed
    24
    26
    50
    46
    38
    29
    Units: Units on a scale
    least squares mean (confidence interval 95%)
        Cycle 2 Day 1, n=24,26,50,46,38,29
    0.01 (-0.04 to 0.05)
    0.04 (-0.01 to 0.08)
    -0.01 (-0.04 to 0.02)
    0.02 (-0.01 to 0.05)
    -0.02 (-0.05 to 0.02)
    0.01 (-0.03 to 0.05)
        Cycle 3 Day 1, n=24,26,50,46,38,29
    -0.01 (-0.05 to 0.03)
    0.01 (-0.03 to 0.05)
    0.01 (-0.02 to 0.04)
    -0.01 (-0.04 to 0.02)
    -0.01 (-0.05 to 0.02)
    -0.01 (-0.05 to 0.03)
        Cycle 4 Day 1, n=24,26,50,46,38,29
    0.03 (-0.02 to 0.07)
    0.00 (-0.04 to 0.04)
    -0.03 (-0.06 to 0.00)
    -0.02 (-0.05 to 0.01)
    -0.04 (-0.07 to -0.00)
    -0.01 (-0.06 to 0.03)
        Cycle 5 Day 1, n=24,26,50,46,38,29
    -0.01 (-0.05 to 0.03)
    -0.01 (-0.06 to 0.03)
    -0.00 (-0.03 to 0.03)
    0.00 (-0.03 to 0.03)
    -0.04 (-0.08 to -0.01)
    -0.04 (-0.08 to 0.00)
        Cycle 6 Day 1, n=24,26,50,46,38,29
    -0.03 (-0.07 to 0.01)
    0.01 (-0.03 to 0.06)
    -0.02 (-0.05 to 0.01)
    -0.00 (-0.04 to 0.03)
    -0.01 (-0.05 to 0.02)
    -0.02 (-0.07 to 0.02)
        Cycle 8 Day 1, n=24,26,50,46,38,29
    -0.02 (-0.06 to 0.02)
    0.00 (-0.04 to 0.05)
    -0.02 (-0.05 to 0.01)
    -0.03 (-0.06 to 0.01)
    -0.04 (-0.07 to 0.00)
    0.00 (-0.04 to 0.05)
        Cycle 10 Day 1, n=24,26,50,46,38,29
    -0.02 (-0.06 to 0.02)
    0.03 (-0.01 to 0.08)
    -0.02 (-0.06 to 0.01)
    -0.01 (-0.05 to 0.02)
    -0.05 (-0.09 to -0.01)
    -0.04 (-0.08 to 0.01)
        Cycle 12 Day 1, n=24,26,50,46,38,29
    -0.04 (-0.08 to 0.01)
    -0.00 (-0.05 to 0.04)
    -0.02 (-0.06 to 0.02)
    -0.03 (-0.06 to 0.01)
    -0.08 (-0.13 to -0.04)
    -0.01 (-0.05 to 0.04)
        Cycle 14 Day 1, n=24,26,50,46,38,29
    0.02 (-0.04 to 0.07)
    0.02 (-0.03 to 0.08)
    -0.05 (-0.09 to -0.01)
    -0.04 (-0.08 to -0.00)
    -0.02 (-0.07 to 0.04)
    0.01 (-0.05 to 0.06)
        Cycle 16 Day 1, n=24,26,50,46,38,29
    -0.03 (-0.09 to 0.03)
    0.01 (-0.05 to 0.07)
    0.02 (-0.03 to 0.07)
    -0.03 (-0.08 to 0.01)
    -0.04 (-0.14 to 0.06)
    -0.01 (-0.07 to 0.06)
        Cycle 18 Day 1, n=24,26,50,46,38,29
    0.09 (0.01 to 0.18)
    -0.02 (-0.09 to 0.05)
    -0.03 (-0.09 to 0.02)
    -0.06 (-0.11 to -0.01)
    -0.09 (-0.23 to 0.04)
    -0.01 (-0.08 to 0.05)
        Cycle 20 Day 1, n=24,26,50,46,0,29
    0.07 (-0.03 to 0.17)
    0.02 (-0.06 to 0.09)
    0.01 (-0.06 to 0.08)
    -0.09 (-0.16 to -0.03)
    99999 (99999 to 99999)
    -0.03 (-0.11 to 0.04)
        Cycle 22 Day 1, n=24,26,50,46,0,29
    -0.02 (-0.12 to 0.08)
    -0.02 (-0.10 to 0.07)
    0.00 (-0.08 to 0.08)
    -0.08 (-0.16 to 0.00)
    99999 (99999 to 99999)
    -0.05 (-0.13 to 0.03)
        Cycle 24 Day 1, n=24,26,50,46,0,29
    0.03 (-0.11 to 0.16)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    -0.06 (-0.20 to 0.07)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
        End of treatment, n=24,26,50,46,38,29
    -0.04 (-0.13 to 0.04)
    -0.01 (-0.10 to 0.08)
    -0.02 (-0.08 to 0.04)
    -0.05 (-0.10 to -0.00)
    -0.07 (-0.14 to -0.01)
    -0.05 (-0.12 to 0.03)
    No statistical analyses for this end point

    Secondary: Change from Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)

    Close Top of page
    End point title
    Change from Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2) [49]
    End point description
    Identification Test: measure of visual attention and uses well validated choice reaction time paradigm with playing card stimuli. In this, playing cards are all red or black jokers. On-screen instructions ask: “Is card red?”. Playing card is presented face down in center of screen. Card flips over so it is face up. As soon as it flips over participant must decide whether card is red or not. If it is red participant should press “Yes”, if it is not red participant should press “No”. Speed and accuracy of each response are recorded.Mean of log10 transformed reaction time for correct response is calculated. Lower value of least square mean change from baseline=performance decline. Upper limit of 95% CI of -0.00/lower=statistically significant decline of performance over baseline. PRO evaluable analysis set: all enrolled participants who received study treatment, had baseline test assessment, atleast 1 on-study test assessment. Number Analyzed: participants evaluable for specified row.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
    Notes
    [49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2)
    Number of subjects analysed
    24
    26
    50
    46
    38
    29
    Units: Units on a scale
    least squares mean (confidence interval 95%)
        Cycle 2 Day 1, n=24,26,50,46,38,29
    -0.02 (-0.05 to 0.01)
    -0.02 (-0.05 to 0.01)
    -0.01 (-0.03 to 0.00)
    -0.01 (-0.03 to 0.01)
    -0.02 (-0.04 to 0.01)
    -0.01 (-0.04 to 0.02)
        Cycle 3 Day 1, n=24,26,50,46,38,29
    -0.01 (-0.04 to 0.02)
    -0.01 (-0.04 to 0.02)
    -0.02 (-0.04 to 0.00)
    -0.02 (-0.04 to 0.00)
    -0.02 (-0.05 to 0.00)
    -0.01 (-0.04 to 0.02)
        Cycle 4 Day 1, n=24,26,50,46,38,29
    -0.02 (-0.05 to 0.01)
    -0.01 (-0.04 to 0.01)
    -0.02 (-0.04 to 0.00)
    -0.03 (-0.05 to -0.01)
    -0.05 (-0.08 to -0.03)
    -0.02 (-0.04 to 0.01)
        Cycle 5 Day 1, n=24,26,50,46,38,29
    -0.03 (-0.06 to -0.00)
    -0.02 (-0.05 to 0.01)
    -0.03 (-0.05 to -0.00)
    -0.02 (-0.04 to 0.01)
    -0.05 (-0.07 to -0.02)
    -0.02 (-0.05 to 0.00)
        Cycle 6 Day 1, n=24,26,50,46,38,29
    -0.04 (-0.07 to -0.01)
    -0.02 (-0.05 to 0.01)
    -0.02 (-0.04 to 0.00)
    -0.03 (-0.06 to -0.01)
    -0.03 (-0.06 to -0.01)
    -0.03 (-0.06 to -0.00)
        Cycle 8 Day 1, n=24,26,50,46,38,29
    -0.03 (-0.06 to -0.00)
    -0.02 (-0.05 to 0.01)
    -0.03 (-0.05 to -0.01)
    -0.03 (-0.05 to -0.01)
    -0.05 (-0.07 to -0.02)
    -0.03 (-0.06 to 0.00)
        Cycle 10 Day 1, n=24,26,50,46,38,29
    -0.03 (-0.06 to 0.00)
    -0.01 (-0.04 to 0.02)
    -0.03 (-0.05 to -0.01)
    -0.02 (-0.05 to 0.00)
    -0.05 (-0.08 to -0.02)
    -0.03 (-0.06 to 0.00)
        Cycle 12 Day 1, n=24,26,50,46,38,29
    -0.05 (-0.08 to -0.02)
    -0.04 (-0.07 to -0.01)
    -0.04 (-0.06 to -0.01)
    -0.04 (-0.07 to -0.01)
    -0.06 (-0.09 to -0.03)
    -0.03 (-0.06 to 0.00)
        Cycle 14 Day 1, n=24,26,50,46,38,29
    -0.04 (-0.08 to 0.00)
    -0.04 (-0.07 to -0.00)
    -0.03 (-0.06 to -0.00)
    -0.04 (-0.07 to -0.01)
    -0.04 (-0.08 to -0.00)
    -0.02 (-0.06 to 0.02)
        Cycle 16 Day 1, n=24,26,50,46,38,29
    -0.09 (-0.13 to -0.05)
    -0.00 (-0.04 to 0.04)
    -0.03 (-0.07 to 0.01)
    -0.03 (-0.06 to 0.01)
    -0.07 (-0.13 to 0.00)
    -0.06 (-0.10 to -0.01)
        Cycle 18 Day 1, n=24,26,50,46,38,29
    -0.01 (-0.06 to 0.05)
    -0.05 (-0.09 to 0.00)
    -0.04 (-0.08 to 0.00)
    -0.07 (-0.10 to -0.03)
    -0.19 (-0.29 to -0.09)
    -0.01 (-0.05 to 0.04)
        Cycle 20 Day 1, n=24,26,50,46,0,29
    -0.03 (-0.10 to 0.04)
    -0.01 (-0.06 to 0.04)
    -0.03 (-0.08 to 0.02)
    -0.10 (-0.15 to -0.06)
    99999 (99999 to 99999)
    -0.03 (-0.08 to 0.02)
        Cycle 22 Day 1, n=24,26,50,46,0,29
    0.04 (-0.03 to 0.11)
    -0.01 (-0.07 to 0.05)
    -0.06 (-0.11 to 0.00)
    -0.05 (-0.11 to 0.00)
    99999 (99999 to 99999)
    -0.08 (-0.14 to -0.03)
        Cycle 24 Day 1, n=24,26,50,46,0,0
    0.08 (-0.01 to 0.18)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    -0.06 (-0.15 to 0.04)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
        End of treatment, n=24,26,50,46,38,29
    -0.07 (-0.13 to -0.02)
    -0.03 (-0.10 to 0.03)
    -0.02 (-0.06 to 0.02)
    -0.03 (-0.06 to 0.01)
    -0.09 (-0.14 to -0.05)
    -0.06 (-0.11 to -0.01)
    No statistical analyses for this end point

    Secondary: Change from Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)

    Close Top of page
    End point title
    Change from Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2) [50]
    End point description
    One Back Test: measure of working memory and uses well validated n back paradigm with playing cards. In this task, the on-screen instructions ask: “Is previous card same?”. Playing card is presented in center of screen. Participant must decide whether card is same as previous card. If it is same participant should press “Yes”, and if not press “No”. Speed and accuracy of each response are recorded, mean of log10 transformed reaction time for correct response is used to demonstrate speed of performance, arcsine transformation of square root of proportion of correct responses is for demonstrate accuracy. Lower value of least square mean change from baseline= performance decline. Upper limit of 95%CI of -0.00/ lower:statistically significant decline of performance over baseline. PRO evaluable analysis set: all enrolled participants who received study treatment, had baseline test assessment, at least 1 on-study test assessment. Number Analyzed:participants evaluable for specified row.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
    Notes
    [50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2)
    Number of subjects analysed
    24
    26
    50
    46
    38
    29
    Units: Units on a scale
    least squares mean (confidence interval 95%)
        Cycle 2 Day 1, n=24,26,50,46,38,29
    0.01 (-0.02 to 0.05)
    0.02 (-0.01 to 0.05)
    0.02 (0.00 to 0.05)
    0.01 (-0.01 to 0.04)
    0.02 (-0.01 to 0.05)
    0.01 (-0.02 to 0.04)
        Cycle 3 Day 1, n=24,26,50,46,38,29
    0.06 (0.02 to 0.09)
    0.01 (-0.02 to 0.05)
    0.01 (-0.01 to 0.04)
    0.01 (-0.02 to 0.03)
    -0.01 (-0.04 to 0.02)
    -0.00 (-0.04 to 0.03)
        Cycle 4 Day 1, n=24,26,50,46,38,29
    0.04 (0.01 to 0.08)
    0.03 (-0.00 to 0.06)
    0.02 (-0.01 to 0.04)
    -0.01 (-0.04 to 0.01)
    -0.02 (-0.05 to 0.01)
    -0.01 (-0.05 to 0.02)
        Cycle 5 Day 1, n=24,26,50,46,38,29
    0.02 (-0.01 to 0.06)
    0.03 (-0.00 to 0.07)
    0.03 (0.00 to 0.05)
    -0.01 (-0.04 to 0.02)
    -0.02 (-0.05 to 0.01)
    0.02 (-0.01 to 0.05)
        Cycle 6 Day 1, n=24,26,50,46,38,29
    0.03 (-0.01 to 0.06)
    0.03 (-0.00 to 0.07)
    0.03 (0.01 to 0.06)
    0.01 (-0.02 to 0.04)
    -0.00 (-0.03 to 0.03)
    0.01 (-0.03 to 0.04)
        Cycle 8 Day 1, n=24,26,50,46,38,29
    0.03 (-0.01 to 0.06)
    0.02 (-0.02 to 0.06)
    0.03 (0.00 to 0.05)
    0.01 (-0.02 to 0.03)
    -0.01 (-0.04 to 0.02)
    0.01 (-0.02 to 0.05)
        Cycle 10 Day 1, n=24,26,50,46,38,29
    0.07 (0.03 to 0.11)
    0.03 (-0.00 to 0.07)
    0.03 (0.00 to 0.05)
    0.02 (-0.01 to 0.05)
    -0.01 (-0.05 to 0.02)
    0.01 (-0.02 to 0.05)
        Cycle 12 Day 1, n=24,26,50,46,38,29
    0.05 (0.01 to 0.08)
    0.01 (-0.03 to 0.05)
    0.02 (-0.01 to 0.05)
    0.01 (-0.02 to 0.04)
    -0.00 (-0.04 to 0.03)
    0.03 (-0.01 to 0.07)
        Cycle 14 Day 1, n=24,26,50,46,38,29
    0.00 (-0.05 to 0.05)
    0.03 (-0.01 to 0.07)
    0.03 (-0.01 to 0.07)
    -0.00 (-0.04 to 0.03)
    0.01 (-0.04 to 0.06)
    0.02 (-0.03 to 0.07)
        Cycle 16 Day 1, n=24,26,50,46,38,29
    0.03 (-0.03 to 0.08)
    0.05 (-0.01 to 0.10)
    0.05 (0.00 to 0.09)
    -0.02 (-0.05 to 0.02)
    -0.01 (-0.10 to 0.08)
    0.03 (-0.03 to 0.08)
        Cycle 18 Day 1, n=24,26,50,46,38,29
    0.02 (-0.06 to 0.09)
    0.01 (-0.04 to 0.07)
    0.06 (0.02 to 0.11)
    -0.02 (-0.06 to 0.03)
    -0.18 (-0.30 to -0.06)
    0.05 (-0.01 to 0.10)
        Cycle 20 Day 1, n=24,26,50,46,0,29
    -0.06 (-0.15 to 0.03)
    0.07 (0.00 to 0.13)
    0.02 (-0.05 to 0.08)
    -0.01 (-0.06 to 0.05)
    99999 (99999 to 99999)
    0.02 (-0.04 to 0.09)
        Cycle 22 Day 1, n=24,26,50,46,0,29
    0.02 (-0.07 to 0.11)
    0.05 (-0.02 to 0.12)
    0.04 (-0.03 to 0.11)
    -0.07 (-0.14 to 0.00)
    99999 (99999 to 99999)
    0.03 (-0.04 to 0.11)
        Cycle 24 Day 1, n=24,26,50,46,0,0
    0.09 (-0.03 to 0.21)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    0.01 (-0.11 to 0.13)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
        End of treatment, n=24,26,50,46,0,29
    -0.03 (-0.10 to 0.05)
    0.03 (-0.05 to 0.11)
    0.03 (-0.02 to 0.07)
    0.01 (-0.04 to 0.05)
    -0.03 (-0.08 to 0.02)
    0.02 (-0.05 to 0.08)
    No statistical analyses for this end point

    Secondary: Change from Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)

    Close Top of page
    End point title
    Change from Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2) [51]
    End point description
    International Shopping List task: measure of verbal learning,uses well validated list learning paradigm administered using computer. High frequencies, high imagery, concrete nouns (items from a shopping list) were read to participant at rate of one word every 2 seconds. Once all 12 words had been read, participant was asked to recall as many of words as quickly as possible. Words recalled by participant were marked on computer screen. When participant could recall no more words, same list was read again. Words recalled by participant were recorded. This was repeated third time. Total number of correct responses on 3 consecutive trials at single assessment was recorded. Upper limit of 95% CI of -0.00 or lower indicate statistically significant decline of performance over baseline. PRO evaluable analysis set: all enrolled participants who received study treatment, had baseline test assessment, atleast 1 on-study test assessment. Number Analyzed: participant evaluable for specified row.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
    Notes
    [51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2)
    Number of subjects analysed
    24
    26
    50
    46
    38
    29
    Units: Units on a scale
    least squares mean (confidence interval 95%)
        Cycle 2 Day 1, n=24,26,50,46,0,29
    -0.02 (-1.89 to 1.84)
    -1.13 (-2.90 to 0.64)
    0.25 (-1.01 to 1.52)
    -0.45 (-1.76 to 0.86)
    0.96 (-0.50 to 2.43)
    0.16 (-1.51 to 1.83)
        Cycle 3 Day 1, n=24,26,50,46,0,29
    0.19 (-1.66 to 2.03)
    -0.81 (-2.58 to 0.96)
    0.14 (-1.15 to 1.43)
    -1.04 (-2.36 to 0.29)
    -0.08 (-1.59 to 1.44)
    -0.56 (-2.21 to 1.09)
        Cycle 4 Day 1, n=24,26,50,46,0,29
    0.58 (-1.26 to 2.42)
    0.26 (-1.54 to 2.05)
    0.28 (-1.05 to 1.61)
    0.24 (-1.12 to 1.60)
    1.30 (-0.26 to 2.86)
    -0.87 (-2.59 to 0.84)
        Cycle 5 Day 1, n=24,26,50,46,0,29
    1.30 (-0.51 to 3.12)
    -0.66 (-2.53 to 1.21)
    0.59 (-0.77 to 1.95)
    -0.94 (-2.33 to 0.45)
    1.23 (-0.36 to 2.82)
    0.74 (-0.97 to 2.45)
        Cycle 6 Day 1, n=24,26,50,46,0,29
    0.18 (-1.64 to 1.99)
    0.81 (-1.06 to 2.68)
    0.50 (-0.87 to 1.87)
    0.08 (-1.31 to 1.47)
    0.82 (-0.83 to 2.46)
    -0.51 (-2.31 to 1.29)
        Cycle 8 Day 1, n=24,26,50,46,0,29
    0.84 (-1.00 to 2.68)
    0.60 (-1.30 to 2.50)
    1.69 (0.29 to 3.08)
    0.15 (-1.27 to 1.57)
    0.44 (-1.23 to 2.11)
    1.70 (-0.11 to 3.50)
        Cycle 10 Day 1, n=24,26,50,46,0,29
    0.26 (-1.68 to 2.21)
    2.59 (0.65 to 4.52)
    0.86 (-0.56 to 2.27)
    0.13 (-1.46 to 1.72)
    2.29 (0.53 to 4.05)
    0.97 (-0.99 to 2.93)
        Cycle 12 Day 1, n=24,26,50,46,0,29
    2.87 (0.86 to 4.88)
    0.02 (-2.06 to 2.10)
    0.11 (-1.52 to 1.73)
    0.69 (-0.98 to 2.35)
    1.74 (-0.25 to 3.72)
    3.10 (1.06 to 5.14)
        Cycle 14 Day 1, n=24,26,50,46,0,29
    1.91 (-0.71 to 4.53)
    1.46 (-0.85 to 3.78)
    2.27 (0.36 to 4.17)
    0.94 (-0.86 to 2.73)
    -4.43 (-7.11 to -1.75)
    2.67 (0.09 to 5.25)
        Cycle 16 Day 1, n=24,26,50,46,0,29
    4.52 (1.58 to 7.46)
    0.87 (-2.06 to 3.79)
    1.36 (-1.11 to 3.84)
    1.04 (-0.99 to 3.07)
    3.46 (-1.26 to 8.18)
    1.97 (-0.93 to 4.87)
        Cycle 18 Day 1, n=24,26,50,46,0,29
    4.77 (0.82 to 8.73)
    0.66 (-2.50 to 3.81)
    -0.27 (-2.89 to 2.36)
    -0.52 (-2.77 to 1.73)
    -0.35 (-6.90 to 6.21)
    3.13 (0.00 to 6.27)
        Cycle 20 Day 1, n=24,26,50,46,0,29
    -2.72 (-7.47 to 2.03)
    -1.44 (-4.91 to 2.03)
    0.56 (-2.81 to 3.92)
    1.20 (-1.84 to 4.24)
    99999 (99999 to 99999)
    0.56 (-2.89 to 4.01)
        Cycle 22 Day 1, n=24,26,50,46,0,29
    -5.72 (-10.47 to -0.97)
    -0.28 (-4.22 to 3.66)
    2.17 (-1.68 to 6.01)
    -0.36 (-4.21 to 3.48)
    99999 (99999 to 99999)
    3.99 (0.07 to 7.91)
        Cycle 24 Day 1, n=24,26,50,46,0,0
    -8.49 (-15.06 to -1.92)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    -3.35 (-9.86 to 3.16)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
        End of treatment, n=24,26,50,46,38,29
    1.02 (-2.99 to 5.04)
    -1.62 (-5.95 to 2.71)
    0.80 (-1.80 to 3.40)
    -0.27 (-2.47 to 1.92)
    2.37 (-0.54 to 5.27)
    -0.60 (-4.09 to 2.89)
    No statistical analyses for this end point

    Secondary: Change from Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)

    Close Top of page
    End point title
    Change from Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2) [52]
    End point description
    This test was performed in same way as the International Shopping List Test, with exception that, delayed recall condition required participant to recall words from list 15 30 minutes later without having list read again. During recognition condition, qualified personnel read a shopping list item that may or may not have been on original list and participant had to respond either affirmatively (if item was on original list) or negatively (if it was not). Total number of correct responses made in remembering word list after a delay was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% CI of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle. PRO evaluable analysis: all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
    Notes
    [52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2)
    Number of subjects analysed
    24
    26
    50
    46
    38
    29
    Units: Units on a scale
    least squares mean (confidence interval 95%)
        Cycle 2 Day 1, n=24,26,50,46,38,29
    0.10 (-0.85 to 1.06)
    -0.84 (-1.76 to 0.08)
    -0.12 (-0.77 to 0.53)
    -0.59 (-1.28 to 0.09)
    -0.22 (-0.96 to 0.53)
    -0.25 (-1.11 to 0.62)
        Cycle 3 Day 1,n=24,26,50,46,38,29
    -0.33 (-1.28 to 0.62)
    -1.32 (-2.24 to -0.40)
    -0.14 (-0.81 to 0.52)
    -0.77 (-1.46 to -0.07)
    -0.87 (-1.64 to -0.10)
    -0.30 (-1.15 to 0.56)
        Cycle 4 Day 1,n=24,26,50,46,38,29
    -0.44 (-1.38 to 0.50)
    -0.91 (-1.86 to 0.03)
    0.03 (-0.66 to 0.72)
    -0.25 (-0.97 to 0.47)
    -0.02 (-0.82 to 0.78)
    -1.06 (-1.95 to -0.18)
        Cycle 5 Day 1,n=24,26,50,46,38,29
    -0.35 (-1.29 to 0.59)
    -0.57 (-1.54 to 0.40)
    0.02 (-0.69 to 0.73)
    -0.46 (-1.20 to 0.27)
    0.09 (-0.74 to 0.92)
    0.17 (-0.72 to 1.05)
        Cycle 6 Day 1,n=24,26,50,46,38,29
    0.48 (-0.46 to 1.42)
    -0.38 (-1.35 to 0.59)
    0.12 (-0.59 to 0.84)
    -0.22 (-0.95 to 0.52)
    0.30 (-0.55 to 1.15)
    -0.28 (-1.21 to 0.66)
        Cycle 8 Day 1,n=24,26,50,46,38,29
    0.56 (-0.38 to 1.50)
    -0.24 (-1.23 to 0.75)
    0.02 (-0.70 to 0.74)
    -0.49 (-1.24 to 0.25)
    -1.08 (-1.94 to -0.22)
    -0.16 (-1.10 to 0.77)
        Cycle 10 Day 1, n=24,26,50,46,38,29
    0.29 (-0.74 to 1.31)
    0.80 (-0.22 to 1.82)
    0.54 (-0.20 to 1.28)
    0.23 (-0.61 to 1.08)
    0.25 (-0.67 to 1.16)
    -0.00 (-1.02 to 1.02)
        Cycle 12 Day 1,n=24,26,50,46,38,29
    0.90 (-0.15 to 1.95)
    0.13 (-0.95 to 1.21)
    0.22 (-0.63 to 1.07)
    0.19 (-0.70 to 1.07)
    0.60 (-0.43 to 1.64)
    0.42 (-0.64 to 1.49)
        Cycle 14 Day 1, n=24,26,50,46,38,29
    0.38 (-0.99 to 1.75)
    0.06 (-1.15 to 1.27)
    1.06 (0.06 to 2.06)
    0.11 (-0.85 to 1.07)
    -1.80 (-3.31 to -0.30)
    0.35 (-1.00 to 1.71)
        Cycle 16 Day 1, n=24,26,50,46,38,29
    0.89 (-0.66 to 2.43)
    0.52 (-1.02 to 2.05)
    0.68 (-0.62 to 1.98)
    -0.12 (-1.22 to 0.98)
    0.40 (-2.09 to 2.88)
    -0.22 (-1.75 to 1.30)
        Cycle 18 Day 1, n=24,26,50,46,38,29
    1.06 (-1.02 to 3.14)
    0.68 (-0.98 to 2.34)
    0.38 (-1.00 to 1.76)
    -0.24 (-1.54 to 1.07)
    -0.39 (-3.85 to 3.07)
    -0.33 (-1.97 to 1.32)
        Cycle 20 Day 1,n=24,26,50,46,0,29
    -1.22 (-3.73 to 1.28)
    0.16 (-1.67 to 1.98)
    -0.24 (-2.01 to 1.53)
    -0.18 (-1.78 to 1.43)
    99999 (99999 to 99999)
    -0.70 (-2.52 to 1.11)
        Cycle 22 Day 1, n=24,26,50,46,0,29
    -3.22 (-5.73 to -0.72)
    0.68 (-1.40 to 2.76)
    0.80 (-1.23 to 2.83)
    -0.64 (-2.67 to 1.39)
    99999 (99999 to 99999)
    0.37 (-1.70 to 2.43)
        Cycle 24 Day 1, n=24,0,0,46,0,0
    -2.43 (-5.89 to 1.04)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    -0.80 (-4.25 to 2.64)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
        End of treatment,n=24,26,50,46,38,29
    -0.87 (-2.99 to 1.24)
    -2.31 (-4.58 to -0.04)
    0.52 (-0.84 to 1.89)
    -0.85 (-2.06 to 0.35)
    -0.19 (-1.71 to 1.34)
    0.11 (-1.72 to 1.95)
    No statistical analyses for this end point

    Secondary: Number of Participants with Absolute Values and Change from Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy)

    Close Top of page
    End point title
    Number of Participants with Absolute Values and Change from Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy) [53]
    End point description
    PR Interval was determined by ECG measurement. Baseline was defined as the average of the triplicate measurements prior to the first dose of study drug. The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    DDI Substudy Phase 2
    Number of subjects analysed
    32
    272
    Units: Participants
        40-<60 msec
    2
    19
        60-<80 msec
    0
    9
        >=80 msec
    0
    5
    No statistical analyses for this end point

    Other pre-specified: Percentage of Participants with Overall and Intracranial Objective Response (Phase 2 and DDI sub-study)

    Close Top of page
    End point title
    Percentage of Participants with Overall and Intracranial Objective Response (Phase 2 and DDI sub-study) [54]
    End point description
    ITT analysis set was used for overall response assessment and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with central nervous system (CNS) metastases in the ITT analysis set were used for intracranial response assessment. Here, "Number Analyzed" signifies participants evaluable for specified rows.
    End point type
    Other pre-specified
    End point timeframe
    From first dose of study treatment to end of treatment (maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Notes
    [54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint is reporting statistics for the arms specified
    End point values
    EXP-1 (Phase 2) EXP-2 (Phase 2) EXP-3 (Phase 2) EXP-4 (Phase 2) EXP-5 (Phase 2) EXP-6 (Phase 2) DDI Substudy
    Number of subjects analysed
    30
    27
    60
    65
    46
    47
    32
    Units: Percentage of participants
    number (confidence interval 95%)
        OR, n=30,27,60,65,46,47,32
    90.0 (73.5 to 97.9)
    77.8 (57.7 to 91.4)
    56.7 (43.2 to 69.4)
    40.0 (28.0 to 52.9)
    37.0 (23.2 to 52.5)
    38.3 (24.5 to 53.6)
    40.6 (23.7 to 59.4)
        Intracranial OR, n=8,17,33,45,37,25,16
    75.0 (34.9 to 96.8)
    58.8 (32.9 to 81.6)
    66.7 (48.2 to 82.0)
    53.3 (37.9 to 68.3)
    43.2 (27.1 to 60.5)
    56.0 (34.9 to 75.6)
    25.0 (7.3 to 52.4)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)
    Adverse event reporting additional description
    The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    50 mg QD (Phase 1)
    Reporting group description
    PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    25 mg QD (Phase 1)
    Reporting group description
    PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.

    Reporting group title
    10 mg QD (Phase 1)
    Reporting group description
    PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    DDI Substudy
    Reporting group description
    Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1.

    Reporting group title
    35 mg BID (Phase 1)
    Reporting group description
    PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    75 mg BID (Phase 1)
    Reporting group description
    PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    100 mg BID (Phase 1)
    Reporting group description
    PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    Phase 2
    Reporting group description
    Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    Japan Lead-In Cohort (LIC)
    Reporting group description
    Few Japanese participants were given PF-06463922 100 mg orally once daily (QD) in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal to evaluate safety of PF-06463922 in Japanese participants, in order to support inclusion of Japanese participants in Phase 2.

    Reporting group title
    150 mg QD (Phase 1)
    Reporting group description
    PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.

    Reporting group title
    100 mg QD (Phase 1)
    Reporting group description
    PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    75 mg QD (Phase 1)
    Reporting group description
    PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Reporting group title
    200 mg QD (Phase 1)
    Reporting group description
    PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.

    Serious adverse events
    50 mg QD (Phase 1) 25 mg QD (Phase 1) 10 mg QD (Phase 1) DDI Substudy 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) Phase 2 Japan Lead-In Cohort (LIC) 150 mg QD (Phase 1) 100 mg QD (Phase 1) 75 mg QD (Phase 1) 200 mg QD (Phase 1)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 3 (66.67%)
    3 / 3 (100.00%)
    13 / 32 (40.63%)
    2 / 3 (66.67%)
    2 / 3 (66.67%)
    2 / 4 (50.00%)
    135 / 275 (49.09%)
    1 / 3 (33.33%)
    3 / 3 (100.00%)
    10 / 17 (58.82%)
    6 / 12 (50.00%)
    2 / 3 (66.67%)
         number of deaths (all causes)
    0
    1
    1
    1
    0
    1
    0
    32
    1
    2
    3
    1
    0
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Acute leukaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute myeloid leukaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Breast cancer
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colon cancer
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary tumour thrombotic microangiopathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neoplasm progression
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Embolism
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    5 / 275 (1.82%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 5
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Embolism venous
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aortic dissection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypertensive crisis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peripheral artery occlusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Superior vena cava syndrome
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Disease progression
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    5 / 32 (15.63%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    29 / 275 (10.55%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    4 / 17 (23.53%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 5
    0 / 0
    0 / 1
    0 / 0
    0 / 29
    0 / 0
    0 / 1
    0 / 4
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 12
    0 / 0
    0 / 1
    0 / 3
    0 / 1
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    9 / 275 (3.27%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 10
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chest pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peripheral swelling
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Generalised oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gait disturbance
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    8 / 275 (2.91%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 3
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 9
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoxia
         subjects affected / exposed [1]
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 2 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    4 / 275 (1.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 6
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemoptysis
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute respiratory failure
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    3 / 275 (1.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute pulmonary oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea exertional
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epistaxis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed [2]
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 47 (2.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    3 / 275 (1.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    1 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Interstitial lung disease
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    3 / 275 (1.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleuritic pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary congestion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory distress
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary hypertension
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    4 / 275 (1.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wheezing
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asphyxia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peripheral bilateral pulmonary embolism
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Mental status changes
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    4 / 275 (1.45%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 4
    0 / 0
    1 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Confusional state
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    3 / 275 (1.09%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    1 / 3
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Delirium
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    2 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hallucination
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Assisted suicide
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Impulse-control disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Schizophreniform disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lipase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood cholesterol increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ejection fraction decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SARS-CoV-2 test positive
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Subdural haematoma
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    6 / 275 (2.18%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 7
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femoral neck fracture
         subjects affected / exposed [3]
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 47 (4.26%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hip fracture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pelvic fracture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Humerus fracture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post procedural haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rib fracture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Toxicity to various agents
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ankle fracture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thoracic vertebral fracture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Traumatic intracranial haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tendon rupture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Radiation necrosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac arrest
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pericardial effusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    5 / 275 (1.82%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    1 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrioventricular block complete
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sinus node dysfunction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial flutter
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Coronary artery disease
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 3
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhage intracranial
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Presyncope
         subjects affected / exposed [4]
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    1 / 47 (2.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brain oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cognitive disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydrocephalus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Partial seizures
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lacunar stroke
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peripheral sensory neuropathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vagus nerve disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neurological symptom
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brainstem compression
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aphasia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dysarthria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hemiparesis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolic encephalopathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorder
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tremor
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Eye pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cataract
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blepharitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestinal obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal perforation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal wall haematoma
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastric volvulus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Glossitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    3 / 275 (1.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Terminal ileitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Biloma
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Jaundice
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bile duct stenosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholangitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystocholangitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Dermatomyositis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neurogenic bladder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal cyst haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intervertebral disc protrusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal chest pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Muscular weakness
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arthralgia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Influenza
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    19 / 275 (6.91%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    2 / 17 (11.76%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    2 / 33
    0 / 0
    0 / 2
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    4 / 275 (1.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    4 / 275 (1.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 5
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung abscess
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Erysipelas
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    3 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vestibular neuronitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    3 / 275 (1.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia bacteraemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infectious pleural effusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Viral upper respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urethritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypercalcaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperuricaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypertriglyceridaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dehydration
    alternative assessment type: Systematic
         subjects affected / exposed [5]
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Notes
    [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Data is valid
    [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Data is valid
    [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Data is valid
    [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Data is valid
    [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Data is valid
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    50 mg QD (Phase 1) 25 mg QD (Phase 1) 10 mg QD (Phase 1) DDI Substudy 35 mg BID (Phase 1) 75 mg BID (Phase 1) 100 mg BID (Phase 1) Phase 2 Japan Lead-In Cohort (LIC) 150 mg QD (Phase 1) 100 mg QD (Phase 1) 75 mg QD (Phase 1) 200 mg QD (Phase 1)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    32 / 32 (100.00%)
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    4 / 4 (100.00%)
    273 / 275 (99.27%)
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    17 / 17 (100.00%)
    12 / 12 (100.00%)
    3 / 3 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Melanocytic naevus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Tumour pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    1
    0
    0
    0
    0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    35 / 275 (12.73%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 17 (5.88%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    10
    1
    1
    0
    82
    2
    1
    3
    3
    0
    Deep vein thrombosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Haematoma
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Hypotension
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Hot flush
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    0
    0
    1
    0
    0
    Haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Shock
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Raynaud's phenomenon
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Flushing
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    8 / 32 (25.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    40 / 275 (14.55%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 17 (23.53%)
    4 / 12 (33.33%)
    1 / 3 (33.33%)
         occurrences all number
    2
    0
    1
    18
    1
    0
    0
    82
    0
    0
    7
    8
    2
    Mucosal inflammation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    0
    Gait disturbance
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    14 / 275 (5.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    2
    2
    1
    1
    0
    0
    0
    25
    0
    0
    1
    1
    1
    Fatigue
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    4 / 32 (12.50%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    3 / 4 (75.00%)
    50 / 275 (18.18%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    5 / 17 (29.41%)
    5 / 12 (41.67%)
    1 / 3 (33.33%)
         occurrences all number
    0
    1
    1
    5
    0
    1
    5
    90
    0
    4
    8
    6
    3
    Face oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    2
    0
    Chest pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    30 / 275 (10.91%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    1
    0
    42
    0
    0
    2
    0
    0
    Oedema
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    25 / 275 (9.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    2 / 12 (16.67%)
    2 / 3 (66.67%)
         occurrences all number
    1
    1
    0
    1
    0
    1
    1
    34
    0
    0
    0
    3
    2
    Oedema peripheral
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    3 / 3 (100.00%)
    14 / 32 (43.75%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    3 / 4 (75.00%)
    127 / 275 (46.18%)
    1 / 3 (33.33%)
    3 / 3 (100.00%)
    10 / 17 (58.82%)
    4 / 12 (33.33%)
    1 / 3 (33.33%)
         occurrences all number
    1
    1
    3
    31
    0
    3
    7
    238
    1
    7
    17
    7
    1
    Pyrexia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    49 / 275 (17.82%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    3 / 17 (17.65%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    4
    0
    0
    1
    70
    0
    1
    3
    1
    0
    Pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    15 / 275 (5.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    2
    0
    0
    0
    19
    0
    0
    1
    1
    0
    Peripheral swelling
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    4 / 32 (12.50%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    21 / 275 (7.64%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    1
    4
    0
    0
    0
    26
    0
    0
    0
    1
    1
    Axillary pain
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Catheter site extravasation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Chills
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Chest discomfort
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Disease progression
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Generalised oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    1
    0
    0
    0
    Non-cardiac chest pain
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Performance status decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Swelling
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    5 / 275 (1.82%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    4
    0
    0
    0
    5
    0
    0
    0
    0
    0
    Swelling face
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    Seasonal allergy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Social circumstances
    Menopause
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Reproductive system and breast disorders
    Menstruation irregular
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Vaginal haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Dysmenorrhoea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Breast pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Erectile dysfunction
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 3 (66.67%)
    1 / 3 (33.33%)
    7 / 32 (21.88%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 4 (50.00%)
    68 / 275 (24.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    2 / 12 (16.67%)
    1 / 3 (33.33%)
         occurrences all number
    1
    2
    1
    9
    1
    0
    4
    134
    0
    0
    2
    3
    1
    Dysphonia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    13 / 275 (4.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    2
    0
    0
    1
    15
    0
    0
    0
    2
    0
    Dyspnoea
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    10 / 32 (31.25%)
    3 / 3 (100.00%)
    1 / 3 (33.33%)
    2 / 4 (50.00%)
    82 / 275 (29.82%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    4 / 17 (23.53%)
    3 / 12 (25.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    1
    1
    16
    4
    4
    5
    116
    1
    0
    0
    3
    0
    Dyspnoea exertional
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    15 / 275 (5.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    2
    0
    0
    4
    25
    0
    0
    1
    2
    0
    Epistaxis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    1
    0
    0
    Haemoptysis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    2 / 3 (66.67%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Hypoxia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Pleural effusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    15 / 275 (5.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    1
    1
    0
    16
    0
    0
    0
    0
    0
    Wheezing
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Acute respiratory failure
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Bronchitis chronic
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Laryngeal inflammation
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Nasal congestion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Oropharyngeal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    2
    0
    0
    Pulmonary hypertension
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    Pulmonary embolism
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Productive cough
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    15 / 275 (5.45%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    21
    0
    1
    0
    0
    0
    Pleuritic pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    2
    0
    0
    Pulmonary oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Respiratory tract congestion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Rhinorrhoea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Sinus congestion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Rales
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Sleep apnoea syndrome
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Rhinitis allergic
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Lung disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Snoring
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Psychiatric disorders
    Affect lability
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    3 / 12 (25.00%)
    2 / 3 (66.67%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    5
    2
    Anxiety
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    21 / 275 (7.64%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    2
    0
    1
    25
    0
    0
    0
    2
    0
    Insomnia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    30 / 275 (10.91%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    5
    0
    0
    0
    40
    0
    1
    0
    1
    0
    Irritability
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    16 / 275 (5.82%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    2 / 12 (16.67%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    21
    0
    0
    2
    2
    2
    Abnormal dreams
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    1
    Mental status changes
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Hallucination
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    Depressed mood
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    1
    1
    Confusional state
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    11 / 275 (4.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 17 (11.76%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    1
    0
    13
    0
    1
    2
    0
    0
    Bradyphrenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    Agitation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    4 / 275 (1.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    2
    0
    0
    5
    0
    0
    0
    0
    0
    Nightmare
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Sleep disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Reading disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Depression
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    16 / 275 (5.82%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    24
    0
    0
    0
    0
    0
    Hallucination, auditory
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    5 / 275 (1.82%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    4
    0
    0
    0
    7
    2
    0
    0
    0
    0
    Mental disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Attention deficit hyperactivity disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Mania
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Investigations
    Blood cholesterol increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    17 / 32 (53.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    97 / 275 (35.27%)
    3 / 3 (100.00%)
    1 / 3 (33.33%)
    4 / 17 (23.53%)
    6 / 12 (50.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    60
    0
    0
    3
    566
    24
    1
    13
    9
    0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    14 / 275 (5.09%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    5
    0
    1
    0
    44
    22
    0
    7
    0
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 4 (50.00%)
    44 / 275 (16.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    4 / 17 (23.53%)
    3 / 12 (25.00%)
    2 / 3 (66.67%)
         occurrences all number
    1
    1
    0
    6
    0
    0
    8
    109
    1
    0
    9
    6
    3
    Amylase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    35 / 275 (12.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    5 / 17 (29.41%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    3
    35
    0
    0
    2
    119
    0
    0
    18
    3
    1
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    42 / 275 (15.27%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    4 / 17 (23.53%)
    3 / 12 (25.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    4
    0
    0
    5
    97
    2
    0
    8
    5
    0
    Weight increased
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    9 / 32 (28.13%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 4 (50.00%)
    77 / 275 (28.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    4 / 17 (23.53%)
    4 / 12 (33.33%)
    1 / 3 (33.33%)
         occurrences all number
    1
    1
    0
    20
    0
    2
    3
    175
    2
    1
    7
    9
    1
    Lipase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    39 / 275 (14.18%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    5 / 17 (29.41%)
    3 / 12 (25.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    2
    2
    0
    0
    2
    123
    5
    0
    30
    6
    3
    Electrocardiogram QT prolonged
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    19 / 275 (6.91%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    1
    28
    0
    1
    0
    0
    0
    Blood triglycerides increased
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    4 / 32 (12.50%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    17 / 275 (6.18%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    4 / 17 (23.53%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    12
    0
    0
    6
    38
    0
    1
    10
    3
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    1
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    Blood creatinine increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    2
    2
    3
    0
    Blood phosphorus decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Candida test positive
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Ejection fraction decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    2
    0
    0
    2
    0
    0
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 4 (50.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    12
    0
    0
    0
    1
    3
    0
    Glucose urine present
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    International normalised ratio increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Transaminases increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Weight decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Liver function test increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Electrocardiogram PR prolongation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Amino acid level increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Blood glucose increased
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Haemoglobin decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Platelet count decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    10 / 275 (3.64%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    0
    10
    0
    0
    1
    0
    0
    SARS-CoV-2 test positive
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Lipids increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    1
    0
    0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    5 / 32 (15.63%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    17 / 275 (6.18%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    8
    0
    0
    0
    35
    2
    0
    1
    0
    0
    Contusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    Ligament sprain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Joint dislocation
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Incision site pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Limb injury
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Toxicity to various agents
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Road traffic accident
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Skin abrasion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Skin laceration
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Fracture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Spinal fracture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    11 / 275 (4.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    2
    0
    0
    0
    12
    0
    0
    0
    0
    0
    Atrial fibrillation
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Ventricular dysfunction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Sinus tachycardia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Angina pectoris
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Nervous system disorders
    Disturbance in attention
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    13 / 275 (4.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    0
    28
    0
    0
    0
    1
    1
    Cognitive disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    23 / 275 (8.36%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    1 / 17 (5.88%)
    2 / 12 (16.67%)
    1 / 3 (33.33%)
         occurrences all number
    0
    1
    1
    1
    0
    0
    1
    31
    0
    2
    1
    2
    5
    Aphasia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    9 / 275 (3.27%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    2
    2
    0
    1
    0
    9
    0
    0
    0
    0
    1
    Amnesia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    24 / 275 (8.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    41
    0
    0
    1
    0
    2
    Dizziness
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    6 / 32 (18.75%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 4 (50.00%)
    51 / 275 (18.55%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    2
    1
    9
    0
    1
    2
    90
    1
    0
    2
    1
    0
    Peripheral sensory neuropathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    25 / 275 (9.09%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    36
    2
    0
    1
    1
    0
    Paraesthesia
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    8 / 32 (25.00%)
    2 / 3 (66.67%)
    1 / 3 (33.33%)
    2 / 4 (50.00%)
    44 / 275 (16.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 17 (23.53%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    2
    0
    15
    2
    1
    4
    72
    0
    0
    5
    4
    1
    Neuropathy peripheral
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 4 (0.00%)
    42 / 275 (15.27%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    3 / 17 (17.65%)
    4 / 12 (33.33%)
    2 / 3 (66.67%)
         occurrences all number
    1
    0
    2
    4
    0
    2
    0
    51
    0
    3
    3
    6
    6
    Memory impairment
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    36 / 275 (13.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 17 (17.65%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    3
    0
    0
    2
    85
    0
    0
    3
    4
    0
    Headache
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    4 / 32 (12.50%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    2 / 4 (50.00%)
    57 / 275 (20.73%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    2 / 17 (11.76%)
    4 / 12 (33.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    1
    9
    1
    2
    3
    98
    1
    1
    6
    5
    1
    Dysgeusia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    11 / 275 (4.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    1
    11
    0
    0
    0
    2
    0
    Presyncope
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    0
    0
    1
    0
    0
    Slow speech
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 17 (17.65%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    1
    1
    Formication
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Dysarthria
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    4
    0
    0
    0
    1
    0
    0
    1
    0
    0
    1
    1
    Dysaesthesia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Carpal tunnel syndrome
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    1
    0
    Balance disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    7 / 275 (2.55%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    1
    12
    0
    0
    1
    0
    1
    Ataxia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Hemiparesis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    2
    0
    1
    0
    0
    0
    Neurotoxicity
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    5
    0
    0
    Neuralgia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    4 / 275 (1.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    2
    0
    0
    0
    9
    0
    0
    0
    0
    0
    Nervous system disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Migraine
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Mental impairment
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Hypoaesthesia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    3 / 12 (25.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    0
    0
    0
    1
    3
    0
    Partial seizures
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Psychomotor hyperactivity
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Peroneal nerve palsy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Seizure
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Tremor
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    5
    0
    0
    0
    2
    0
    0
    0
    1
    0
    Speech disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    2 / 12 (16.67%)
    1 / 3 (33.33%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    0
    0
    0
    1
    2
    1
    Sensory disturbance
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Brachial plexopathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Bradykinesia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Facial paralysis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Sciatica
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Motor dysfunction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Hyperaesthesia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Sleep deficit
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Syncope
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    0
    0
    1
    0
    0
    Fine motor skill dysfunction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    8 / 32 (25.00%)
    1 / 3 (33.33%)
    2 / 3 (66.67%)
    2 / 4 (50.00%)
    46 / 275 (16.73%)
    0 / 3 (0.00%)
    3 / 3 (100.00%)
    7 / 17 (41.18%)
    3 / 12 (25.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    17
    1
    4
    2
    101
    0
    5
    22
    4
    1
    Thrombocytopenia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    1
    0
    0
    0
    0
    0
    0
    0
    2
    1
    0
    Thrombocytosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Neutropenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    8
    0
    0
    Leukocytosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    3 / 275 (1.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    3
    0
    0
    0
    2
    0
    Iron deficiency anaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Haemorrhagic diathesis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Febrile neutropenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Ear and labyrinth disorders
    Tinnitus
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    25 / 275 (9.09%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    3 / 17 (17.65%)
    3 / 12 (25.00%)
    0 / 3 (0.00%)
         occurrences all number
    3
    0
    0
    4
    0
    0
    3
    37
    1
    1
    4
    4
    0
    Vertigo positional
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Vertigo
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    1
    Hypoacusis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    3
    0
    Ear discomfort
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Deafness
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Tympanic membrane perforation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    Ear pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Eye disorders
    Visual impairment
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    15 / 275 (5.45%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    1
    0
    3
    0
    0
    0
    23
    0
    3
    0
    1
    1
    Vision blurred
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    16 / 275 (5.82%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    20
    0
    0
    2
    1
    2
    Dry eye
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Diplopia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Conjunctival oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Astigmatism
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Asthenopia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Presbyopia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Retinal vein occlusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Visual acuity reduced
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    2
    0
    Photopsia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    0
    0
    Photophobia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Retinal detachment
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 4 (50.00%)
    22 / 275 (8.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    2 / 12 (16.67%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    4
    32
    0
    0
    3
    2
    1
    Abdominal distension
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    7 / 32 (21.88%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    20 / 275 (7.27%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    9
    0
    0
    0
    24
    0
    0
    1
    0
    0
    Vomiting
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 4 (50.00%)
    43 / 275 (15.64%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 17 (17.65%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    1
    2
    0
    3
    0
    0
    6
    59
    0
    0
    5
    1
    0
    Nausea
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    3 / 4 (75.00%)
    59 / 275 (21.45%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    4 / 17 (23.53%)
    3 / 12 (25.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    1
    1
    3
    0
    1
    5
    83
    1
    0
    5
    3
    1
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    20 / 275 (7.27%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 17 (17.65%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    1
    0
    22
    0
    0
    4
    1
    0
    Dysphagia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    17 / 275 (6.18%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    2 / 12 (16.67%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    4
    0
    0
    0
    17
    0
    0
    0
    2
    1
    Dyspepsia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Diarrhoea
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    5 / 32 (15.63%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 4 (75.00%)
    69 / 275 (25.09%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    4 / 17 (23.53%)
    3 / 12 (25.00%)
    2 / 3 (66.67%)
         occurrences all number
    1
    0
    0
    6
    0
    0
    5
    122
    0
    1
    5
    7
    4
    Constipation
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    8 / 32 (25.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    50 / 275 (18.18%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 17 (23.53%)
    3 / 12 (25.00%)
    2 / 3 (66.67%)
         occurrences all number
    0
    1
    0
    13
    1
    2
    0
    76
    0
    0
    5
    3
    2
    Abdominal discomfort
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    4 / 275 (1.45%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    1
    0
    7
    0
    1
    0
    0
    0
    Abdominal pain upper
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    3 / 32 (9.38%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    2 / 4 (50.00%)
    15 / 275 (5.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    1
    4
    1
    1
    2
    22
    0
    0
    0
    0
    0
    Faeces discoloured
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Gastrointestinal disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Intestinal obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Swollen tongue
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Ascites
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Dry mouth
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    12 / 275 (4.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    3
    0
    0
    0
    12
    0
    0
    1
    0
    0
    Stomatitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    14 / 275 (5.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    19
    0
    0
    0
    0
    0
    Colitis ulcerative
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Dental caries
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    10 / 32 (31.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    2
    0
    Diarrhoea haemorrhagic
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Food poisoning
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Terminal ileitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Pancreatic disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Oesophagitis
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Tooth impacted
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Flatulence
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 32 (12.50%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    9 / 275 (3.27%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    4
    0
    0
    0
    10
    0
    0
    0
    0
    0
    Hepatobiliary disorders
    Hypertransaminasaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Hepatic cytolysis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    18 / 275 (6.55%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    1
    20
    1
    0
    1
    1
    2
    Dry skin
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    1
    0
    1
    0
    2
    0
    0
    Rash
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    33 / 275 (12.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    3 / 12 (25.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    1
    5
    0
    0
    0
    49
    0
    0
    1
    4
    0
    Pruritus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    11 / 275 (4.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    3
    0
    0
    0
    14
    0
    0
    0
    0
    0
    Hyperhidrosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    19 / 275 (6.91%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    20
    0
    0
    0
    2
    0
    Dermatitis acneiform
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Dermatitis contact
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Dermatomyositis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Night sweats
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Photosensitivity reaction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    1
    Rash erythematous
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Rash maculo-papular
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    3
    0
    0
    Rash pruritic
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Rosacea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Seborrhoeic dermatitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Skin lesion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Erythema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Dermatitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Eczema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Rash papular
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Lipohypertrophy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Hand dermatitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    14 / 275 (5.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    20
    0
    0
    2
    1
    0
    Pollakiuria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Micturition urgency
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Hydronephrosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Chronic kidney disease
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Proteinuria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    1
    0
    0
    Urinary incontinence
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    1
    1
    0
    0
    Dysuria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Renal colic
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Endocrine disorders
    Cushingoid
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Hyperparathyroidism
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Hypothyroidism
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    6 / 32 (18.75%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    84 / 275 (30.55%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    6 / 17 (35.29%)
    3 / 12 (25.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    1
    3
    9
    0
    1
    1
    138
    1
    0
    12
    4
    1
    Back pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    6 / 32 (18.75%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 4 (50.00%)
    45 / 275 (16.36%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    6 / 17 (35.29%)
    2 / 12 (16.67%)
    2 / 3 (66.67%)
         occurrences all number
    0
    1
    0
    7
    0
    3
    2
    63
    1
    0
    11
    2
    4
    Bone pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 32 (12.50%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    8 / 275 (2.91%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    4
    0
    0
    0
    8
    0
    0
    1
    1
    0
    Joint swelling
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Muscle spasms
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    19 / 275 (6.91%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    1
    22
    0
    0
    0
    0
    0
    Muscular weakness
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    18 / 275 (6.55%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    1
    2
    0
    0
    0
    22
    0
    0
    1
    1
    0
    Musculoskeletal chest pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    11 / 275 (4.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    12
    0
    0
    2
    0
    0
    Musculoskeletal pain
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    7 / 275 (2.55%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 17 (23.53%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    2
    0
    0
    0
    9
    0
    0
    5
    0
    0
    Myalgia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    5 / 32 (15.63%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    38 / 275 (13.82%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    7
    0
    1
    1
    50
    3
    0
    2
    3
    0
    Pain in extremity
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    5 / 32 (15.63%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    50 / 275 (18.18%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 17 (11.76%)
    2 / 12 (16.67%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    8
    0
    4
    0
    64
    0
    1
    2
    2
    1
    Arthritis
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Bone lesion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Flank pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 17 (17.65%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    0
    0
    Limb discomfort
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Musculoskeletal discomfort
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Neck pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    8 / 275 (2.91%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 17 (17.65%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    0
    9
    0
    0
    3
    1
    0
    Osteoarthritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Osteoporosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Pain in jaw
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Plantar fasciitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 17 (11.76%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Torticollis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Musculoskeletal stiffness
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Joint lock
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Synovial cyst
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Sacral pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Osteonecrosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Trismus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Spinal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    3 / 275 (1.09%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    3
    0
    0
    0
    0
    0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    20 / 275 (7.27%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 17 (11.76%)
    2 / 12 (16.67%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    1
    0
    4
    4
    30
    0
    1
    6
    2
    1
    Influenza
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    17 / 275 (6.18%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    24
    0
    0
    1
    0
    1
    Pneumonia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 32 (12.50%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    27 / 275 (9.82%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    0
    0
    4
    0
    0
    1
    37
    1
    1
    0
    0
    0
    Rhinitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    16 / 275 (5.82%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    2
    26
    0
    0
    0
    2
    0
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    38 / 275 (13.82%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    4 / 17 (23.53%)
    3 / 12 (25.00%)
    2 / 3 (66.67%)
         occurrences all number
    2
    1
    0
    4
    0
    0
    0
    61
    0
    1
    8
    12
    3
    Sinusitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    2
    0
    Viral upper respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Bacterial infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Candida infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Cellulitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Chronic sinusitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Clostridium difficile colitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Enteritis infectious
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Gastroenteritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Enterococcal bacteraemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Helicobacter infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    0
    Laryngitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 17 (17.65%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    Herpes virus infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    24 / 275 (8.73%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    31
    3
    0
    0
    0
    0
    Oral candidiasis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    2 / 275 (0.73%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    2
    0
    0
    1
    0
    0
    Periodontitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Pharyngitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    1
    0
    0
    Respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 17 (17.65%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    1
    0
    Soft tissue infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Tooth abscess
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Urinary tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 32 (12.50%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    20 / 275 (7.27%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 17 (23.53%)
    1 / 12 (8.33%)
    2 / 3 (66.67%)
         occurrences all number
    0
    0
    0
    4
    0
    0
    1
    28
    0
    0
    8
    2
    3
    Viral rhinitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Conjunctivitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Herpes zoster
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Cystitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    0
    0
    Ear infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Enterocolitis infectious
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    Paronychia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    2
    0
    Pyelonephritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Tooth infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    1
    0
    0
    Viral infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    3
    1
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    26 / 275 (9.45%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    5
    0
    6
    0
    0
    0
    76
    0
    0
    12
    0
    0
    Hypercholesterolaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 3 (66.67%)
    1 / 3 (33.33%)
    15 / 32 (46.88%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    153 / 275 (55.64%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    12 / 17 (70.59%)
    7 / 12 (58.33%)
    3 / 3 (100.00%)
         occurrences all number
    2
    6
    1
    91
    1
    17
    8
    789
    0
    4
    68
    38
    21
    Decreased appetite
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 4 (50.00%)
    18 / 275 (6.55%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    3
    20
    0
    0
    1
    0
    0
    Hypophosphataemia
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    1 / 3 (33.33%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    19 / 275 (6.91%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    0
    5
    1
    0
    0
    0
    0
    43
    0
    4
    0
    0
    4
    Hypomagnesaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    17 / 275 (6.18%)
    0 / 3 (0.00%)
    3 / 3 (100.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    1
    2
    0
    0
    1
    0
    0
    27
    0
    5
    0
    0
    0
    Hypokalaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 32 (9.38%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    18 / 275 (6.55%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    1 / 3 (33.33%)
         occurrences all number
    1
    0
    0
    4
    1
    0
    0
    30
    0
    7
    1
    0
    16
    Hyperuricaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 32 (3.13%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    19 / 275 (6.91%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    1
    24
    1
    1
    0
    0
    0
    Hypertriglyceridaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    23 / 32 (71.88%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 4 (25.00%)
    179 / 275 (65.09%)
    3 / 3 (100.00%)
    1 / 3 (33.33%)
    7 / 17 (41.18%)
    5 / 12 (41.67%)
    2 / 3 (66.67%)
         occurrences all number
    4
    9
    0
    137
    0
    3
    11
    1273
    33
    1
    74
    10
    11
    Hyperlipidaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Dehydration
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    1 / 12 (8.33%)
    1 / 3 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    1
    1
    Hypercalcaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Fluid retention
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    7 / 275 (2.55%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    2 / 12 (16.67%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    3
    1
    0
    0
    8
    0
    0
    0
    2
    0
    Hypocalcaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    0
    0
    0
    Hypoalbuminaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    16 / 275 (5.82%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    26
    0
    0
    0
    0
    0
    Increased appetite
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Hyperkalaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 17 (5.88%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Cell death
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 32 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 4 (25.00%)
    0 / 275 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    4
    0
    0
    0
    0
    0
    0
    Gout
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    1 / 275 (0.36%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    0
    2
    0
    0
    0
    0
    0
    Hyponatraemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 32 (6.25%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 4 (0.00%)
    10 / 275 (3.64%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 17 (0.00%)
    0 / 12 (0.00%)
    0 / 3 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    0
    14
    0
    0
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    17 Sep 2013
    Added left ventricular ejection fraction (LVEF) evaluation, exclusion criterion about LVEF, secondary efficacy measures, specific DLT definition and dose modification in case of toxicity.
    28 Mar 2014
    Updated Schedule of Activities; revised inclusion and exclusion criteria; updated DLT definition and clarified intra-subject dose escalation.
    29 Oct 2014
    Added lipid testing, a food effect substudy, neurological assessment, BID dosing, Japanese LIC; revised inclusion and exclusion criteria.
    22 Jul 2015
    Revised inclusion and exclusion criteria; removed midazolam, food effect and some other assessments from Phase 2; added cognition, mood and suicidal ideation and behavior assessment in Phase 2.
    11 Mar 2016
    Excluded subjects with PR interval >220 msec, or 2nd or 3rd degree atrioventricular block within 3 months prior to study entry; added dose modification for subjects with PR interval prolongation.
    15 Jul 2016
    Added Drug Drug Interaction, Holter Monitoring; updated dose modification for those with 1st, 2nd degree or complete heart block; deleted restriction for taking proton pump inhibitors with study drug.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Participant with ALK/ROS1positive NSCLC were enrolled in EXP-1 to EXP-6 cohort,received 100mg dose.Primary safety population=participant had atleast 1dose of lorlatinib.Sample size N=275 provided more valuable information than single expansion cohort
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 17:47:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA